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ABSTRACT OF THE DISSERTATION 
Using Fluorescence-Polarization Endoscopy in Detection of Precancerous and Cancerous 
Lesions in Colon and Pancreatic cancer  
By 
Tauseef Charanya 
Doctor of Philosophy in Biomedical Engineering 
Washington University in St. Louis, 2015 
Professor Samuel Achilefu, Chair 
 
Colitis-associated cancer (CAC) arises from premalignant flat lesions of the colon, which 
are difficult to detect with current endoscopic screening approaches. We have developed a 
complementary fluorescence and polarization reporting strategy that combines the unique 
biochemical and physical properties of dysplasia and cancer for real time detection of these lesions. 
Utilizing a new thermoresponsive sol-gel formulation with targeted molecular probe allowed 
topical application and detection of precancerous and cancerous lesions during endoscopy. 
VII 
 
Incorporation of nanowire-filtered polarization imaging into NIR fluorescence endoscopy served 
as a validation strategy prior to obtaining biopsies.  
In order to reduce repeat surgeries arising from incomplete tumor resection, we 
demonstrated the efficacy of the targeted molecular probe towards margins of sporadic colorectal 
cancer (SCC). Fluorescence-polarization microscopy using circular polarized (CP) light served as 
a rapid, supplementary tool for assessment and validation of excised tissue to ensure complete 
tumor resection for examining tumor margins prior to H&E-based pathological diagnosis. We 
extended our platform towards non-invasive directed detection of pancreatic cancer utilizing 
fluorescence molecular tomography (FMT) and NIR laparoscopy using identified targeted 
molecular probe. We were able to non-invasively distinguished between pancreatitis and 
pancreatic cancer and guide pancreatic tumor resection using NIR laparoscopy.  
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1.1 Overview of Doctoral Research and Dissertation 
 
 My doctoral research focuses on the development of an endoscope capable of detecting 
near infrared (NIR) fluorescence and tissue-sensitive polarized light information from suspect 
colon cancer lesions. During this doctoral study, I have identified a targeting molecular probe for 
detection of precancerous and cancerous lesions, explored delivery routes of molecular probes for 
in vivo application, and demonstrated the use of the novel fluorescence-polarization endoscopy 
and associated microscopy. The dissertation is structured as follows: Chapter 1 is an introduction 
to sporadic and colitis-associated cancer (CAC), targeted NIR molecular imaging, and 
fluorescence-polarization imaging. Chapters 2-6 derive in large part from published journal 
manuscripts or manuscripts in preparation, where I was a lead author. Chapter 7 presents a concise 
summary of the dissertation with conclusions. 
 
1.2 Epidemiology and Clinical Standards in Staging and Treatment of 
Colorectal Cancer 
 
1.2.1 Sporadic colorectal cancer (SCC) and colitis-associated cancer (CAC)  
 
Every year in the United States alone, there are 160,000 cases of colorectal cancer 
diagnosed, and 57,000 reported deaths making it the second leading cause of death from cancer 
amongst adults1. Colorectal cancer (CRC) can be divided into two primary categories: sporadic 
colorectal cancer (SCC) and colitis-associated cancer (CAC). While sporadic colorectal cancer is 
more common, it is known that people who suffer from inflammatory bowel disease (IBD), 
comprised of Crohn’s disease and ulcerative colitis, are at a greater risk of developing CAC. As 
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many as 1.4 million people in the United States alone suffer from IBD. A meta-analysis of 
colorectal cancer risk suggests a cumulative incidence of malignancy of 2% by 10 years, 8% by 
20 years and 18% by 30 years post diagnosis2. Because the peak onset of this disease occurs in the 
second and third decades of life, these patients are subject to a two-fold or greater lifetime risk of 
developing colorectal cancer than normal subjects3 
Both, SCC and CAC arise from pre-cancerous dysplastic mucosa4. However, 
approximately 67% of sporadic colorectal cancers arise from polyps, whereas colitis-associated 
cancers typically arise from flat dysplastic mucosa.  In CAC, evidence for dysfunctional signaling 
in the Wingless (Wnt) signaling pathway, due to the adenomatous polyposis coli (APC) mutation, 
occurs late in the dysplasia-cancer sequence. This late occurrence likely is why polyps do not form 
in dysplasia-driven cancer in CAC5. Conversely, p53 mutation occurs at a relatively early stage in 
CAC, as shown in Figure 16. Furthermore, duplication of chromosome 17p, which contains p53, 
is common even in non-dysplastic colitis of the epithelium, affecting 22% of epithelial cells, 10% 
of cells in normal mucosa, and 37% of the cells high-grade dysplasia and cancer7. For treating 
colorectal cancer patients, it is crucial to identify both these lesions, flat and polypoid, for improved 
diagnosis and establishment of treatment regime. 
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Figure 1. Mutation sequences in CAC and SCC  
 
In conventional practice, diagnosis of colonic polyps is governed by gold standard 
approaches, such as endoscopic polypectomy, that rely primarily on the trained eye of the 
physicians performing the procedure8. Diagnosis of small premalignant lesions and early-stage 
primary tumors is crucial for the success of cancer therapy and increases survival rates. While 
surveillance endoscopy is the clinical standard for detection and resection of suspicious colonic 
cancerous lesions, the lack of an elevated growth component, such as polyps in the case of CAC, 
make it challenging to detect flat lesions during surveillance colonoscopy. Studies have shown up 
that up to 50-80% of the lesions that are missed during surveillance colonoscopy are flat9,10. Hence, 
interest has increased within the past decade in fluorescence-based and other optical imaging 
techniques for clinical oncology.  
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1.2.2 Staging and Treatment in Colorectal Cancer 
By convention, staging of colon cancer is based on tumor size/invasiveness/histology by tumor 
node metastasis (TNM) staging. These invasive cancers can be completely curable by resection if they 
remain confined to the wall of the colon: mucosa-submucosa (T1-2, N0, M0 and T3-4, N0, M0). However, 
as the tumor invades past the muscle layers and serosa, it spreads to nearby organs (T1-4, N1-2, M0) or to 
even distant organs (T any, N any, M1) through lymph node involvement, making it extremely difficult to 
resect and leading to possible recurrence 11,12.  
 
Figure 2. Staging of colorectal cancer  
 
As shown in Figure 2, in stage 0, abnormal cells are found in the innermost layer of the colon wall 
and may become cancer and spread. In Stage 1, cancer has formed in the mucosa of the colon wall and has 
spread to the submucosal layer. There is a chance that the cancer may have already spread to the muscle 
layer of the colon wall. In Stage 2 IIA, cancer has spread through the muscle layer of the colon wall to the 
serosa (outermost layer) of the colon wall. In Stage IIB, cancer has spread through the serosa but has not 
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spread to the nearby organs. In Stage IIC, cancer has spread through the serosa of the colon to nearby 
organs. In Stage IIIA the cancer has spread to at least one but not more than three nearby lymph nodes, or 
cancer cells have formed in tissues near the lymph nodes. In Stage IIIB, cancer has spread to at least four 
but not more than six lymph nodes. In Stage IIIC, the cancer has spread through the serosa of the colon wall 
and to nearby organs. In Stage IVA, cancer has spread through the colon wall and to one organ that is not 
near the colon such as liver, lung or kidney. Last, in Stage IVB, cancer has spread through the colon wall 
to nearby organs or lymph nodes and spread to more than one organ that is not near the colon.  
Colonoscopy plays an extremely important role in the care of patients with colorectal cancer as it 
is not only used for diagnosis of different stages of colorectal cancer but also treatment of early colorectal 
cancer and its precursors. While diagnostic challenges in early stages of colorectal cancer (lesions <1 cm 
and flat in nature) still persist, treatment for colorectal neoplastic lesions typically begins with hot biopsy 
and snare polpectomy, and endoscopic submucosal resection (EMR). In the case of large and flat lesions, 
techniques such as endoscopic submucosal dissection (ESD) are usually employed. EMR is an endoscopic 
technique developed for removal of sessile or flat neoplasms that are confined to the superficial mucosal 
layers (mucosa and submucosa) of the GI tract13. It is typically used for removal of lesions that are smaller 
than 2 cm. ESD, on the other hand, has specifically been developed for en bloc removal of large (more than 
2 cm), flat GI tract lesions14,15. Pathological examination utilizing gold standard hematoxylin and eosin 
(H&E) stains of biopsy specimen is conducted in order to confirm the stage and complete diagnosis of the 
colorectal cancer patient. However, the EMR technique has yielded recurrence rates as high as 55% in some 
studies 16,17. Lymph node metastasis with/without organ involvement in N0 is known to have a recurrence 
of 20%-30% and that of 50%-80% in T1-4, N1-2, M0 after surgery 18. The high recurrence rates are highly 
attributed to incomplete tumor resection and late stage diagnosis. To address this, efforts have been directed 
primarily to early diagnosis of colon cancer via specific structural or functional characteristics that are 
specific to colon cancer. 
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1.3 Existing Detection Methods in Colitis-Associated Cancer 
 Recent developments in imaging technologies and the validation of newer imaging 
techniques may lead to significant improvements in the management of patients with colorectal 
cancer. Diagnostic techniques that are based primarily on structural information include, but are 
not limited to, high resolution microendoscopy (HRME), optical coherence tomorgraphy (OCT), 
narrow-band imaging (NBI), and computed tomography colonography (CTC) to name a few. 
Techniques that are based primarily on functional information include and are not limited to 
chromoendoscopy (CE), confocal laser endomicroscopy (CLE), and targeted molecular 
endoscopy. These technologies are briefly described below: 
 
1.3.1 High-Resolution Microendoscopy (HRME) 
HRME is a novel method for imaging colorectal mucosa at a subcellular level, with up to 
a 1000X magnification and resolution as fine as 4.4 µm. Developed by Muldoon et al., the device 
is flexible portable, and consists of 30,000 optical fibers in a 1 mm diameter bundle. The device 
typically uses light-emitting diode (LED) illumination and is connected to a charge-coupled device 
(CCD) camera19. Given its small size, it can be easily inserted in the accessory channel of the 
colonoscope to visualize sub-cellular characteristics of polyp mucosa.    
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Figure 3: Fiber-optic micro endoscopy system. a) Schematic, b) fiber-optic bundle diameters, 
compared on a US penny19. Bundles one and two have outer diameters of 1 mm and 0.5 mm 
respectively. 
 
 Chang et al. further demonstrated the use of the HRME system in the colon20. The system 
was operated as a compact, battery-powered fluorescence microscope, coupled to a 1 mm diameter 
fiberoptic imaging probe. LED illumination was delivered from the HRME unit, through the 
imaging probe, to the tissue surface. In acquisition mode, the fluorescence light returning to the 
bundle was directed to a CCD that transmitted real-time images to a computer at 12 frames per 
second (fps), as shown in the schematic in Figure 320.   
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Figure 4. Use of HRME probe during colonoscopy procedure20. The top image is a wide field view 
of the colon, showing an illuminated polyp. While the polyp under white light as shown in (a) is 
inconclusive for diagnosis, the HRME image (b) is able to provide diagnosis regarding neoplasia 
or lack thereof in polyps. (c) Validated finding in H&E image20.  
 
While HRME provides the ability to distinguish neoplastic polyps from benign polyps with 
a sensitivity of 67%, a specificity of 97%, and accuracy of 87%, the utilization of this technique 
in identifying flat lesions in colitis-associated cancer remains problematic. Also, the HRME 
technique requires an expert endoscopist to identify the polyp in the first place using white light, 
prior to using the HRME probe for a closer microscopic examination and diagnosis. The inability 
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to distinguish flat lesions from their surroundings makes this technique very challenging, and time-
intensive for this purpose.  
 
1.3.2 Optical Coherence Tomography (OCT) 
 OCT obtains cross-sectional images of target tissue with high resolution, on the order of a 
low power microscope. OCT utilizes a technique known as interferometry that measures the path 
length of reflected light and processes the information for image generation. While OCT is very 
similar to ultrasound, except that it uses light as a signal instead of sound signal, OCT obtains 
images that correlate with the subsurface of the tissue. Sergeev et al. were one of the first groups 
to demonstrate the use of OCT imaging in precancerous and cancerous states of human mucosa21. 
They demonstrated the use of this system in identifying an esophageal tumor in the stomach as 
shown in Figure 11.  
 
 
Figure 10. Distal end of the gastroscope with OCT probe, along with schematic of scanning unit 
on the right: 1; output lens, 2; output glass window, 3; sample. 
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Figure 11. OCT image of healthy esophagus (left) and esophageal tumor in the stomach. E: 
epithelium, LP: lamina propia, SM: smooth muscle, ML: muscularis layer, BV: blood vessel 
 
  Due to their different backscattering intensities, the different mucosa layers can be 
identified. For example, the stratified squamous epithelium (E) appears as a weakly scattering 
layer, while the lamina propia appears as the most scattering layer. Furthermore, the muscularis 
mucosa (ML), the minimally backscattering layer, appears as a dark stripe. Also, deep layers that 
are submucosa (more backscattering) can be differentiated from muscular layers (less 
backscattering). Vessels and glands in the lamina propia (LP) are visible as circular or elongated 
formations. While endoscopic OCT can identify differences in well-defined stratified healthy 
mucosa in cancerous tissues, it does have limitations, such as non-real-time acquisition and a 
length procedural time.  
 To provide faster real-time imaging with high resolution, developments have been made 
towards frequency domain OCT22. Volumetric laser endomicroscopy can provide a resolution of 
10 µm and imaging depth up to 3 mm. It can scan a 6 cm length of esophagus tissue in a minute 
and a half. This device has also gained clearance from the FDA. Furthermore, Tearney et al. has 
developed a capsule containing optical frequency domain imaging (OFDI) technology-that is 
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composed of a rotating laser tip emitting a beam of NIR light and sensors that record reflected 
backscattered light from esophageal lining. This imaging platform allows for several OCT images 
for the esophagus during a five minute procedure as the pill is swallowed by the patient and 
controlled via a tether externally by the physician23.  
 
1.3.3 Narrow Band Imaging (NBI) 
 NBI is an optical imaging enhancement technology that improves the visibility of blood 
vessels and other structures on the mucosa. It has demonstrated tremendous potential in tumor 
detection in the colon due to enhanced vascularization associated with tumors. Basically, NBI 
filters white light into specific shorter light wavelengths, 540 nm and 415 nm that are absorbed by 
hemoglobin and penetrate only the surface of human tissue. This method takes advantage of the 
phenomena that shorter wavelengths penetrate only the superficial layers of the mucosa, allowing 
capillaries to be displayed in brown on a video image. The 540 nm light penetrates deeper than 
415 nm light and is absorbed by blood vessels located deeper within the mucosal layer, appearing 
cyan on the NBI image. The wavelength is particularly useful for detecting tumors due to enhanced 
vasculature appearing as brown while veins are displayed in cyan. The NBI system uses optical 
filters of blue (440-460 nm) and green (540-560 nm) wavelength, which enhance the visualization 
of blood vessels and mucosal pit patterns24.  
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Figure 7. Narrow band imaging (NBI) uses two wavelengths, 415 nm and 540 nm, for enhanced 
visualization of blood vessels (Olympus, America). 
 
 However, whether the NBI system actually helps to improve colonic polyp detection 
remains controversial. Recently published meta-analyses failed to demonstrate any superiority of 
current NBI over white light endoscopy in detecting colon polyps25-27. The older version of the 
NBI yielded dimmer images, making it difficult to distinguish polyps or detect adenoma, while the 
newly available second generation of NBI provides a two-fold brighter image. Leung et al. 
compared the miss rates of adenomas using the new NBI system to WL colonoscopy and recorded 
a miss rate differential of 21.5% using the new NBI system24. They did, however, notice an 
improvement in the polyp detection rate of 14% over white light colonoscopy. Figure 8 
demonstrates the appearance of a colorectal polyp utilizing a second generation NBI scope in a 
close-up and distant view.  
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Figure 8. (a) Close-up and (b) distant view of a colorectal polyp using NBI. White arrows in (a) 
and (b) indicate a polyp at a closer and further view, respectively. Yellow arrow in (b) indicates a 
flat lesion. 
 
1.3.4 Virtual CT colonoscopy (CTC) 
 CT colonography is a non-invasive radiological technique that combines a CT scanner and 
reconstruction methods to provide an accurate method to screen for large colorectal polyps and 
cancer. CTC is a quick, minimally invasive procedure that requires no anesthesia. A CT scanner 
obtains hundreds of X-ray images of the entire colon, and reconstruction algorithms allow for two 
or three dimensional images of the colon. While this technique is not recommended for everyone 
due to the low dose of radiation involved, it is recommended for individuals who have ulcerative 
colitis or Crohn’s disease as a pre-existing condition.  
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Figure 9. 3-D reconstructed colonography showing a growth protruding to the lumen of the colon. 
The image on the left represents a reconstructed CT of the whole colon from the exterior. The 
image in the middle represents a reconstructed CT showing the interior of the lumen. Image of the 
right represents a white light image of the same region shown by image in the middle.  
 
 Johnson et al. have demonstrated that polyps greater than 10 mm in diameter are identified 
by CTC experts with detection rates that range from 75% to 95%28. However, this detection 
sensitivity drastically drops when investigating flat lesions of the colon. In a study of 547 patients, 
Fidler et al. demonstrated that CTC detection sensitivities for all flat lesions and flat adenomas 
ranged from 65% and 100% to 15% and 13% amongst expert reviewers29. The drastic inter-
observer variability in detection of flat lesions via CTC primarily arises from perception errors. 
Furthermore, reading CT colonographies requires a high level of expertise, making it difficult to 
substitute for white light colonoscopy as a gold standard.  
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1.3.5 Chromoendoscopy 
In chromoendoscopy (CE), dye is sprayed onto the colonic mucosa using a catheter passed 
through the working channel of the endoscope. Used with dyes, a high resolution or high 
magnification endoscope, allows for detailed evaluation of the mucosal surface9. Inexpensive dyes 
such as methylene blue are used, and are absorbed by intestinal epithelium after local application. 
The result is a relatively stable staining pattern, which allows visualization of the openings of the 
glandular pits during chromoendoscopy30,31. In a study of 1000 patients undergoing routine 
colonoscopy, Rembacken et al. demonstrated that chromoendoscopy improved early diagnosis of 
adenomas and early colorectal cancers32.  
Kiesslich et al. performed a further systematic study to compare diagnoses via conventional 
white light endoscopy and chromoendoscopy in patients with a longstanding history of UC. They 
established that CE differentiated neoplastic from non-neoplastic changes with high specificity 
and sensitivity. CE using methylene blue demonstrated a three-fold increase in the number of 
detected intraepithelial neoplasias. Figures 10 and 11 excerpted from their study, demonstrate the 
ability of chromoendoscopy to help identify low-grade intraepithelial neoplasia and high-grade 
intraepithelial neoplasia respectively.  
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Figure 10. Low-grade intraepithelial neoplasia identified by chromoendoscopy31. Arrows in (a) 
identify the low-grade intraepithelial neoplasia that is further magnified in (b). 
 
 
Figure 11. High-grade intraepithelial neoplasia identified by chromoendoscopy31  
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 CE is often used in routine practice to identify low and high grade neoplasia. However, this 
technique does increase the procedure time by at least 33% and still requires very careful 
examination by the endoscopist. Furthermore, the contrast between low-grade intraepithelial 
neoplasia and the surrounding mucosa is very minimal. While it does help define pit patterns such 
as those present in high grade neoplasia, it cannot provide contrast between diseased and 
surrounding uninvolved regions for a quicker diagnosis and subsequent complete resection. To 
that end, there have been efforts in developing targeting molecular agents to specifically 
distinguish precancerous and cancerous lesions from surrounding uninvolved tissue. 
 
1.3.6 Confocal Laser Endomicroscopy (CLE) 
 In confocal Laser endomicroscopy (CLE) is based on tissue illumination with low-power 
laser light pulses, and the entitled fluorescence from the tissue passes through a single mode optical 
fiber on the main optical axis between the objective lens and the detector. Both the illumination 
and collection systems are aligned in the same focal plane. The laser light is focused at a selected 
depth in the tissue of interest, and the fluorescence is refocused onto the detection system by the 
same lens. A high numerical aperture (NA) lens is used to illuminate and collect light to achieve 
subcellular resolution with maximum light collection. Only the refocused light through the fiber 
is detected while the remaining light, scattered at different geometric angles, is excluded from 
detection, which improves the spatial resolution of confocal endomicroscopy. Confocal 
endomicroscopy allows high resolution optical sectioning over a small field-of-view (FOV), and 
it can also be scaled down to millimeter dimensions. The size of the FOV is further constrained 
because the overall package must be less than 5 mm in diameter for endoscopic application. While 
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confocal imaging is possible based purely on tissue reflectance, confocal systems based on 
fluorescence arising from targeted contrast agents have been extensively developed.  
 In scanning fiber endoscopy (SFE), a single-mode optical fiber is driven by a tubular 
piezoelectric actuator to scan in a spiral pattern by tubular piezoelectric actuator in order to 
create an image with a large FOV. Red, green, and blue laser light (440, 532, and 635 nm 
wavelengths) is delivered through the scanning fiber and focused on to the tissue of interest by a 
multi-lens assembly at the distal tip of the probe. Both reflected and emitted fluorescent light are 
then collected by a ring of multimode optical fibers arranged along the outer edge of the 
instrument. This technology has been used in diagnosing cancer of the esophagus, pancreatic 
duct, and airways using reflected white light33,34.  
 The SFE system has also been used to collect fluorescence in molecular imaging. Wang 
et al. have demonstrated the use of topically applied fluorescein dye on colonic mucosa to 
distinguish between normal mucosa, hyperplasia and adenoma35. Figure 12 shows the 
endomicroscopic probe, which fits into the instrument channel of a working endoscope, and 
shows the endoscope in use.  
. 
Figure 12. Probe based confocal laser endomicroscopy35 
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Figure 13. Colonic fluorescence distribution with corresponding H&E in (a) normal mucosa, (b) 
hyperplasia, (c) tubular adenoma, and (d) villous adenoma35 Scale bar, 40 µm. The crypt lumens 
(L), apical (AP), and basolateral (BL) borders of epithelial cells (C), and lamina propria (LP) can 
be distinguished. 
 
  The fiber based endoscope is small and flexible enough to be used in existing scopes, and 
provide images that demonstrate a striking resemblance to histology when using a contrast agent 
such as fluorescein. Nevertheless, it is restricted to a working distance of 0 microns (direct contact), 
which limits its use in flat lesions, unless they have been already distinguished from their 
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surroundings. Furthermore, acquisition is time-intensive as the acquisition rate is as low as 0.8 
frames per second.  
 
1.4 Targeted NIR Fluorescence Imaging 
 
1.4.1 Fluorescence Imaging 
 Fluorescence imaging is known for its high detection sensitivity, specificity, and spatial 
resolution. It is based on the molecular absorption of light: a region of interest containing the 
fluorophore is excited at a specific wavelength, and light at a different wavelength is emitted. Each 
fluorophore has characteristic excitation spectrum that is identified by monitoring the fluorescence 
emission while the fluorophore is excited by a range of consecutive wavelengths. When electrons 
go from an excited state to the ground state, there is loss of vibrational energy.  As shown in Figure 
14, the emission spectrum is shifted to longer wavelengths than the excitation spectrum (a 
phenomenon known as Stoke’s shift). The emission intensity peak is lower than the excitation 
peak. In order to achieve maximum fluorescence intensity, the flurophore is usually excited at the 
peak wavelength of the excitation curve, and the emission detection is typically the peak 
wavelength of the emission curve.  The fluorescence method is regenerative, allowing longitudinal 
imaging, unlike the radionuclide decay process in nuclear imaging. Each fluorescence emitting 
molecule can be excited multiple times to produce almost the same fluorescence intensity, unless 
there are other diminishing factors, such as photobleaching, that could interfere with the 
process36.37 
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Fig 14. Excitation and Emission Spectra of a given flurophore  
 
1.4.2 NIR Fluorescence Imaging 
 Fluorescence imaging can both use intrinsic tissue properties as a contrast 
(autofluorescence) and also can image exogenous contrast agents. The three primary processes 
that typically govern interaction of photons with tissues include light absorption, light scattering 
and fluorescence emission. Photons interact with tissues by absorption, scattering, and 
fluorescence emission. In short, light absorption and scattering decrease with increasing 
wavelength. Below 700 nm, tissue absorption results in low light penetration depth (a few 
millimeters), allowing only superficial assessment of tissues in the visible wavelength. The light 
absorption is caused by oxy- and deoxy-hemoglobin, by melanin at wavelengths <700 nm, and by 
lipid, and water at wavelengths >1000 nm38,39. Because the absorption coefficient of tissue is 
significantly lower in the near infrared (NIR) region (700-900 nm) than in the visible region, NIR 
light can penetrate more deeply into tissues, to depths of several centimeters40,41. A major goal of 
optical imaging has been the development of suitable targeted NIR fluorochromes with high molar 
extinction coefficients, good quantum yields, and specific tissue binding. 
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Figure 15. Tissue constituents absorbing in the 600 – 1000 nm range42 
 
 Due to the minimal NIR fluorescence contrast generated by most tissues, most in vivo 
studies require exogenous contrast agents. One important class of organic flurophores, hetamethine 
cyanines, comprised the benzoxazole, bezothiazole, idolyl, 2-quinoline and 4-quinoline 
subclasses. Indocyanines are the most widely used among these as they are free from aggregation 
problems associated with the other subclasses. The excitation peak of this class lies between 760-
800 nm, and emission peak is between 790-830 nm43. Indocyanine green (ICG), one of the most 
common examples of indocyanine class, was approved by FDA for in-human use in 1958. It is one 
of the least toxic agents administered to humans, with the only adverse reaction being rare 
anaphylaxis. Furthermore, ICG is tetra-sulfonated, increasing its solubility and aqueous quantum 
yield (QY)39. 
 In vivo imaging requires that the contrast agent be delivered to the target, have adequate 
contact time with the target for the binding to occur, and be retained by the target while non-bound 
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material is cleared. Unconjugated organic NIR flurophores are typically less than 1.2 kDa but have 
widely different bio-distributions and pharmacokinetics, depending on their charge and the 
properties of their conjugated targeted molecule. As the charge per molecule is increased, 
fluorophores remain extracellular and their plasma half-life increases proportionally44.  Clearance 
is typically accomplished by a combination of renal filtration and excretion into bile. 
 Another important consideration for in vivo molecular probes is toxicity. Without charged 
groups, indocyanines can be quite toxic due to intracellular accumulation45. However, di-
sulfonated ICG has been used in humans over 50 years and has an excellent safety profile. ICG 
has been used in a variety of applications, including angiograms of the eye46,47, brain post-tumor 
resection margin determination 48,49, and GI tract lesion identification to name a few. Although 
ICG provides a contrast mechanism, its enhanced permeability and retention (EPR) create 
limitations. Studies utilizing ICG to detect colorectal tumors have demonstrated high background 
intensity in the subserosa around the tumor, resulting in unnecessary follow-up procedures 50. For 
this reason, interest in developing tumor-specific optical contrast agents has been rapidly growing. 
 
1.4.3 Targeted Molecular Imaging 
 Targeted molecular agents consist of a signal component and a targeting component. To 
recognize specific pathological tissues, a mass of targeting component, such as a small molecule, 
peptide, antibody, or aptamer is applied to ligand-directed imaging agents. 
 Small molecules are defined by a size <500 Da. Due to their small size, they can be applied 
to intracellular imaging and even to central nervous system imaging, crossing the blood/brain 
barrier. A common targeted small molecule, 18F-FDG, has been clinically applied to a wide variety 
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of cancer imaging51. Other examples include, but are not limited to, the use of gadolinium (Gd) 
targeting human tumor telomerase reverse transcriptase (hTERT) for detection of telomerase 
positive carcinomas using magnetic resonance imaging52.  
 Peptide, a widely used class of ligands for molecular imaging, offer superior selectivity 
and specificity and easy modification without changing their binding properties or distribution. 
Furthermore, peptides have higher stability and lower immunogenicity than antibodies, making 
them more desirable for imaging. Achilefu et al. conjugated of GRD-based peptide to a NIR 
fluorophore, cypate, for imaging A549 tumor-bearing mice, with the results shown in Figure 1653. 
The versatility of peptides in various modalities is evident from their use in micro-PET imaging 
as well. Hackel et al. employed 18F labeled 2 cysteine knot to detect BxPc3 pancreatic 
adenocarcinoma tumors in mice, using micro-PET with high tumor uptake and demonstrating 
promise for cancer imaging54.  
 
Figure 16. In vivo distribution of Cyp-GRD in A549 tumor-bearing mice53. A) White light image 
of mouse highlighting tumor prior to injection of probe. B) Post-injection, 0 hr image. C) 24 hour 
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post administration image. D) Biodistribution study post sacrifice. E) Blocking study 
demonstrating absence of binding in tumors. 
 
 Antibodies are characterized by their ability to bind to targets due to their high affinity and 
specificity and their easy synthesis. Thus far, there have been more antibody-based targeting 
moieties cleared by the FDA than any other type; with eight FDA approved radiolabeled antibodies 
for SPECT imaging and 20 antibodies approved for therapy. For example, Zhang et al. used PET 
with 64Cu-NOTA-TRC105-Fab to image CD105 expression. Figure 17 showed clear uptake in 4T1 
luc tumors55.  
 
 
Figure 17. PET images of 64Cu-NOTA-TRC105-Fab after treatment with blocking dose of 
TRC105 before injection.55 Arrow marks the location of the tumor. The tumor is identified using 
the probe as opposed to when it is blocked having saturated the target site. Liver shows maximum 
signal uptake. 
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 Molecular imaging enables both dynamic and quantitative visualization of specific 
biochemical processes. It has demonstrated its impact on early stage diagnosis, curative effect 
monitoring of diseases, drug development, gene therapy, and other fields. Its limitations stem from 
a dearth of multifunctional molecular imaging agents, the limitations of imaging technology (such 
as poor sensitivity to complement contrast agents), and the lack of non-radiative molecular 
imaging that can provide both structural and functional information. Although multi-modality 
imaging systems such as PET/MRI have clear advantages in sensitivity and specificity, they are 
more costly than single modality imaging, their performance is not markedly better, and they suffer 
from multimodal contrast agent fusion56. 
 
1.5 Polarization Imaging: Concepts and Application in vivo Imaging 
While molecular imaging can report molecular-sensitive biochemical processes, it still requires 
a modality capable of providing structural information. Efforts have come in the form of color-
fluorescence endoscopy, PET-CT, and even fluorescence-based confocal endomicroscopy (CLE). 
However, such dual-modal approaches have limitations in detection of flat lesions in CAC. Color-
fluorescence imaging lacks a targeting probe that can detect both precancerous and cancerous 
lesions with high specificity and sensitivity and provide a high signal-to-background ratio (SBR). 
PET-CT is far too large to fit within an endoscope. Fluorescence CLE requires further development 
to provide a greater working distance and acquisition rate in an endoscopic setting. To address 
this, we have explored the potential of utilizing polarization-sensitive information to provide 
supplementary structural information about the f tissue of interest in endoscopy. Polarization 
imaging offers an additional contrast mechanism because it allows for discrimination against 
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multiply scattered light, enabling higher resolution imaging of tissues and their underlying 
structures. It provides a method for non-invasive and quantitative tissue diagnosis since the 
polarimetric characteristics of tissues can encode a large amount of biochemical, morphological, 
and functional information57. 
 
1.5.1 Fundamentals of Polarization Imaging 
 Polarization is a consequence of the electromagnetic (EM) wave nature of light, in which 
the transverse oscillations of the electric and magnetic field vectors (Ē and B) trace out stationary 
curves. If the electric and magnetic vectors instead followed random paths in their temporal 
evolution, the resulting light would be said to be unpolarized. The shape of the function traced out 
by the vectors would be defined as the polarization state of the beam.  
 
Figure 18. Electromagnetic Wave 
 
 When the electric field vector Ē of an EM wave is confined to a plane, the resulting light 
is said known to be linearly polarized, and when it traces out a helix normal to the direction of the 
wave’s propagation, the resulting beam is known to be circularly polarized. When considering a 
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large number of photons, their collective behavior is consistent with the classical limit (wave 
solution to Maxwell’s equations), and in the case when all the photons in a beam of light exhibit 
the same polarization, the light is said to be fully polarized. In the case of photons possessing 
different polarizations but with a distribution favoring one particular state, the light is considered 
partially polarized. Lastly, when the photons are uniformly distributed over all polarization states 
the light is said to be unpolarized. The degree of polarization (DOP) emerges as a very useful 
quantification in this case, where it measures the uniformity, or lack thereof. The DOP of fully 
polarized light is 1, and that of unpolarized light is 0. Depending on the magnitude of the relative 
surplus of a particular polarization state, a partially polarized beam of light can fall somewhere 
between the fully polarized and unpolarized light states.  Usually, two mathematical formulations 
describe the polarization state: the Jones calculus and Stokes-Mueller calculus. While the Jones 
calculus is a field-based model which assumes coherent addition of phase and amplitude of EM 
waves, Stokes-Mueller calculus is an intensity-based model which utilizes incoherent addition of 
intensities. That said, the Jones calculus method is limited: It can describe pure polarization states, 
but in biological imaging cases where partially polarized states need to be addressed, it is ill suited. 
Stokes-Mueller formalism, on the other hand, can fully describe polarized light and its interaction 
with materials, thus suiting biomedical polarimetry.  
 
1.5.2 The Stokes-Mueller formalism  
 Polarization states are described by four measurable quantities, known as Stokes 
parameters and denoted I, Q, U, and V relative to six different intensity measurements, each 
corresponding to the intensity of the beam in question after it has passed through various ideal 
polarizers. IH is the intensity through a horizontal linear polarizer, IV through a vertical linear 
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polarizer, IP and IM through linear polarizers at 45
0 and 1350, and IR and IL through right and left 
circular polarizers, respectively. Combining I, Q, U, and V forms a four-dimensional vector, 
known as the Stokes vector:  
     𝑆 =  [
𝐼
𝑄
𝑈
𝑉
] = [
𝐼𝐻 + 𝐼𝑉
𝐼𝐻 − 𝐼𝑉
𝐼𝑃 − 𝐼𝑀
𝐼𝑅 − 𝐼𝐿
]    (1) 
Here, I represents the total intensity of light, Q and U represent the degree and orientation of linear 
polarization, and V represents the degree and direction of circular polarization.  The Stokes 
parameters are related by  
𝐼2 ≥ 𝑄2 + 𝑈2 + 𝑉2    (2)  
   
The equality holds in the case of full polarization, and the inequality holds in the case of partial 
polarization. Therefore, DOP is defined by 
𝐷𝑂𝑃 =  
√𝑄2+ 𝑈2+ 𝑉2
𝐼
    (3)  
 
In the case of an unpolarized beam (DOP = 0), we have Q = V + U = 0. Therefore, the degree of 
linear polarization (DOLP) is defined by 
     𝐷𝑂𝐿𝑃 =  
√𝑄2+ 𝑈2
𝐼
    (4) 
. 
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When light that is described by the Stokes vector Sin interacts with a material, its polarization state 
is usually modified, and the resulting light can be described by the Stokes vector Sout. The resultant 
transfer function between the input and output polarization states can be given by 
      𝑆𝑜𝑢𝑡 = 𝑀𝑆𝑖𝑛    (5) 
Here M is a 4 x 4 matrix known as the Mueller matrix. Expanding the equation above into its 
components results in 
     [
𝐼𝑜𝑢𝑡
𝑄𝑜𝑢𝑡
𝑈𝑜𝑢𝑡
𝑉𝑜𝑢𝑡
] =
[
 
 
 
𝑀1,1 𝑀1,2
𝑀2,1 𝑀2,2
     𝑀1,3 𝑀1,4
    𝑀2,3 𝑀2,4
𝑀3,1 𝑀3,2
𝑀4,1 𝑀4,2
     𝑀3,3 𝑀3,4
    𝑀4,3 𝑀4,4]
 
 
 
[
𝐼𝑖𝑛
𝑄𝑖𝑛
𝑈𝑖𝑛
𝑉𝑖𝑛
]   (6) 
Given that Mueller matrices provide a complete description of a wide range of physical materials, 
and that their elements are associated with various intensities, they can be experimentally 
determined with ease by using conventional intensity-measuring instruments such as polarimeters.  
 
1.5.3 Polarimeteric characteristics 
 The three principle characteristics that can be encoded by a Mueller matrix include 
depolarization, diattenuation, and retardance. In biomedical applications such as tissue imaging 
and characterization, there is a strong need to measure signals that retain their original 
polarization. Biological tissues are strongly depolarizing by multiple scattering and/or 
birefringence domains of varying magnitude and orientation, depolarized noise that can inhibit 
detection of remaining weak remaining information-carrying polarization signals.  
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1.5.3.1 Depolarization 
 If the DOP of incident light is m (between 0 and 1), and the light resulting from 
interaction with the sample has a DOP of n, where (m > n), then the sample is said to be 
depolarizing. For incident beam polarized light m; 
𝑚 = 
√𝑄𝑖𝑛
2+ 𝑈𝑖𝑛
2+ 𝑉𝑖𝑛
2
𝐼
       (7) 
The DOP of the resultant light would be defined as: 
𝑛 =   
√𝑄𝑜𝑢𝑡
2+ 𝑈𝑜𝑢𝑡
2+ 𝑉𝑜𝑢𝑡
2
I
 =   
√(𝑎𝑄𝑖𝑛)
2
+ (𝑏𝑈𝑖𝑛)
2
+ (𝑐𝑉𝑖𝑛)
2
𝐼
              (8) 
Here |𝑎|, |𝑏|, |𝑐| < 1. In matrix form, this relation can be given as 
               𝑀∆ =  [
1     0     
0 𝑎
 
0 0
0 0
0     0     
0 0
 
𝑏 0
0 𝑐
]   |𝑎|, |𝑏|, |𝑐|  ≤ 1     (9) 
Thus 1- |𝑎| and 1 -|𝑏| are linear depolarization factors, and 1 - |𝑐| is the circular depolarization 
factor. The net depolarization, given by delta, is defined as 
∆ = 1 − 
|𝑎|+|𝑏|+ |𝑐|
3
= 1 − 
|𝑇𝑟 (𝑀∆−1)|
3
    (10) 
In biomedical applications, the dominant processes causing depolarization are multiple scattering 
and spatially heterogeneous arrangements of uniaxial birefringent domains. A larger delta 
implies a lower degree of polarization of light after interaction with a medium. 
 Diattenuation and retardance are both the result of differences in refractive indices for 
different polarization states, and they are usually described in terms of the ordinary and 
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extraordinary axis and indices. Differences in the real parts of indices result in linear and circular 
birefringence (retardance), whereas differences in imaginary parts can cause linear and circular 
dichroism (diattenuation). Diattenuation is a measure of the differential attenuation of orthogonal 
polarization states for linear and circular polarization. Therefore, linear diattenuation can be 
described as differential attenuation of two orthogonal linear polarization states, and circular 
diattenuation is the difference between the right and left circular polarization states.  
 Although biological tissues are not easily amenable to polarimetric investigation due to 
the extensive polarization loss caused by multiple scattering and by spatially-varying 
birefringence, it is possible to reliably detect surviving polarization states after fully polarized 
light is shined on the tissue. Several issues remain, including how to reliably measure and 
characterize the surviving fraction, how to interpret the measured polarization signals, and how 
the signal for real-time polarization sensing in an in vivo setting. We have made significant 
efforts on that front, while combining the resulting information with other functional level 
information via targeted NIR fluorescence.  
 
1.6 Our Approach 
In order to address the poor miss rates of flat lesions, we have developed a four-step approach: 
(1) Identifying and characterizing a targeted molecular probe capable of identifying precancerous 
and cancerous lesions in CAC, (2) Exploring administration routes for the molecular probe in 
clinically relevant murine models, (3) Developing the supporting instrumentation for a color-
fluorescence-polarization endoscope, (4) Demonstrating the probe and endoscope in diagnosis and 
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validation post-biopsy of SCC and CAC (5) Expanding the scope of the platform to include other 
disease models. 
 
1.6.1 Choice of Molecular Probe for Colorectal Cancer detection 
A targeted, NIR probe termed LS301 was reported previously58. The probe is composed of a 
NIR fluorescent dye, cypate (780ex/ 830 em), and a cyclic peptide sequence, D-Cys-Gly-Arg-Asp-Ser-Pro-
Cys-Lys (c(DCGRDSPC)K). Figure 19 shows the molecular structure, absorption, and emission spectra of 
LS301. The versatility of this molecular probe in detecting precancerous and cancerous lesions in a variety 
of cancers has been demonstrated for lung cancer cells A54953, the mammary tumor cell line 4T1 luc, 
colorectal cancer cell line HT-29, and even pancreatic cancer in murine models. Figure 20 demonstrates its 
efficacy in 4T1luc tumor bearing mice transfected with luciferase for bioluminescence imaging, in 
comparison to NIR fluorescence.  
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Figure 19. Molecular Structure and excitation/emission characteristics of NIR fluorescence targeted 
LS301 
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Figure 20. Targeted molecular probe LS301 for tumor imaging in 4T1luc tumor-bearing mice 
 
We first employed LS301 on murine colorectal cancer tissue sections derived from various stages 
in and tested its binding preferences. Figures 21 and 22 demonstrate the performance of LS301 with various 
stages (cancerous and dysplastic, respectively) of CAC in an azoxymethane-dextran sodium sulfate (AOM-
DSS) model. AOM-DSS model has been used to demonstrate that advanced cancers develop from 
flat lesions without transitioning through a polypoid intermediate.59 H&E staining and 
corresponding NIR fluorescence are presented for adenomatous tumor (Figure 21) as well as 
dysplastic tissue (Figure 22). A preferential uptake of LS301 is observed in these abnormalities 
when compared to surrounding uninvolved tissue. 
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Figure 21. Binding preference of LS301 for an advanced cancerous stage in AOM-DSS model 
(recapitulates CAC). Arrows are shown to help visualize corresponding regions in H&E and NIR 
fluorescence images. 
 
Figure 21. Binding preference of LS301 for a dysplastic stage in the AOM-DSS model 
(recapitulates CAC). Arrows are shown to help visualize corresponding regions in H&E and NIR 
fluorescence images. 
38 
 
To compare the specificity of our molecular probe for multiple stages of tumorigenesis with 
existing peptide based probes, we conjugated the VRPMPLQ sequence, identified by Contag et al. for its 
preferential binding to colonic dysplastic tissues, to cypate for binding studies60. This conjugated molecular 
probe was termed LS656. The molecular structure, along with the absorbance and emission spectra for 
LS656 and LS301, is presented in Figure 22. Consistent with the findings of Contag et al., LS656 
demonstrated high specificity for precancerous lesions that exhibited features, such as aberrant crypt foci 
(Figure 22g, 22h). LS301 exhibited a very similar binding pattern, to that of LS656 producing higher 
fluorescence intensity at the aberrant crypt foci (Figure 22f). The molecular probes were topically 
administered at a 1uM concentration in a phosphate buffered saline (PBS) solution. LS301 (Figure 22c) 
exhibited a five-fold higher fluorescence intensity than LS656 (Figure 22d), demonstrating its potential as 
a diagnostic tool for multiple stages of tumorigenesis in colorectal cancer. 
 
Figure 22. Comparison of binding preferences of LS301 and LS656 in an AOM-DSS model. (A) Molecular 
structure and emission spectra of LS656 and (B) LS301.  
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 We demonstrated the use of LS301 in a murine sporadic colorectal cancer model as well as a 
spontaneous one (APC min). The sporadic colorectal cancer model was developed by using a human colon 
cancer patient-derived cell line (HT-29) and orthotopically implanting it in the cecal wall using a protocol 
that has been established before.61 We demonstrated the efficacy of the molecular probe over time and 
investigated its binding preferences at an optimal time point, in vivo and ex vivo after exteriorizing the 
organs and sectioning the tissues. Furthermore, we compared the binding preferences of the molecular 
probe with established proliferation marker, Bromodeoxyuridine. This work has resulted in a manuscript, 
details of which can be found in Chapter 2 of this dissertation. 
  
1.6.2 Administration routes for LS301 
Having demonstrated the specificity of LS301 for both precancerous dysplastic lesions in 
colon tissue and cancerous tissue, we then explored the administration routes for LS301 for in 
vivo diagnosis of CAC. Current clinical practice for routine endoscopy requires the patient to be 
on a strict liquid diet one-three days prior to the procedure. Furthermore, they are sometimes 
even subjected to a barium enema solution to empty their bowel. The use of absorptive stains, 
such as methylene blue, during colonoscopy procedures has become an increasingly more 
standard practice to improve visualization during the procedure. These stains have been shown to 
identify specific epithelial cell types by preferential absorption or diffusion across the cell 
membrane. Contrast stains, such as indigo carmine, seep through mucosal crevices and highlight 
surface topography and mucosal irregularities. While these stains aid in visual identification of 
pit patterns, they are not specific towards precancerous and cancerous lesions. The additional 
time required for chromoendoscopy varies dramatically depending on the technique used and 
operator experience as it involves a brief incubation period of up to ten minutes on average62. 
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Other administration routes that are also utilized in abdominal imaging include - but are not 
limited to - intravenous or oral administration. All three administration routes have been 
explored for LS301 and discussed in further detail in Chapter 3.  
 
1.6.3 Developing the supporting instrumentation for color-fluorescence-polarization 
endoscope 
To improve detection sensitivity for flat lesions in colorectal cancer, newer fluorescence 
endoscopic techniques, such as confocal laser endomicroscopy, have been developed. In 
conjunction with fluorescence contrast agents, these techniques allow visualization of molecular 
signatures of cancer, but they lack real-time validation strategy and provide only a limited field of 
view.60,63,64Although fluorescence endoscopy is a well-established method with targeted 
fluorescence imaging gaining more traction in CLE setting, to the best of our knowledge, this has 
been the first demonstration of a combined color-fluorescence-polarization endoscopy in vivo. 
Polarization imaging generally requires the use of complicated setups and multiple measurements, 
making its use in biomedical applications difficult.  
 Herein, we report a novel polarization sensor developed by the Gruev group at Washington 
University. A nanowire polarization filter was fabricated in close collaboration with Moxtek Inc. 
First, a 70 nm thin film of aluminum was deposited on doped Si substrate, followed by a 30 nm 
film deposition of SiO2 by e-beam evaporation. A 100 nm thin layer of photoresist S-1805 was 
spin coated at 3000 rpm and baked at 115oC for 60 seconds. A continuous-wave 532 nm Nd:YAQ 
laser was used with frequency-doubler to produce coherent light waves at 266 nm. Two continuous 
266 nm waves were aligned to interfere at 110 degrees and produce an interference pattern with a 
41 
 
period of 140 nm. The interference pattern was transferred to the photoresist by exposing the 
sample for 40 seconds. After the photoresist was developed, the pattern was transferred to the SiO2 
using the standard RIE/ICP etching procedure for SiO2. The SiO2 is used as a hard mask for etching 
the aluminum. The aluminum was etched for 150 seconds using 30 sccm BCl3, 15 sccm Cl2, 10 
mTorr pressure, 70o C temperature, 100 W RIE power and 150W ICP power. The procedure was 
repeated four times and the sample was rotated by 45o each time in order to produce nanowires 
with four different orientations65. 
 
 
  Figure 23. Block diagram of integrated CCD polarization imaging sensor65  
 Furthermore, we combined the polarization sensor and NIR-fluorescence-sensitive sensor 
that has the ability to also capture color images into endoscopic setup. This setup would allow the 
user to switch between polarization and fluorescence-color modes by simply switching light source 
and camera. Figure 24 demonstrates the setup of the endoscope that allows us to take color, 
fluorescence and polarization sensitive images of a given region of interest in the colon of murine 
models. The setup is fixed on a tripod to minimize movements when switching between 
fluorescence and polarization modes, and has been discussed in greater detail in Chapter 4 and in 
published manuscript66. 
42 
 
 
Figure 24. A color-fluorescence-polarization imaging setup for murine endoscopy  
 
1.6.4 Demonstrating use in colitis-associated cancer, sporadic colorectal cancer for 
diagnosis and validation post-biopsy 
 
Dysplasia in the colon in IBD and CAC develops as a result of repeated cycles of epithelial 
cell injury and repair while cells are bathed in chronic inflammatory cytokine enviornment67. 
While both, spontaneous and colitis-associated cancers share the adenocarcinoma 
consequence, the sequence of underlying molecular events differs, as discussed earlier. The 
azoxymethane-dextran sodium sulfate (AOM-DSS) model fills this void. Dextran sodium 
sulfate (DSS) is an agent that has direct toxic effects on colonic epithelium and can be 
administered in drinking water to mice in multiple cycles to create a chronic inflammatory 
state68. Tumor development can be hastened in this model if it is administered in a pro-
carcinogenic setting such as using azoxymethane (AOM), a tumor-inducing agent. The AOM-
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DSS model has been widely appreciated for its reproducibility, potency, and ease of use. Figure 
25 demonstrates the outcome of this model 72 days post AOM-DSS treatment69.  
 
 
Figure 25. Use of AOM-DSS protocol in formation of adenocarcinoma along the distal and 
proximal colon. (a) normal colon, (b-c) adenomatous tumor highlighted as regions 1 ad 2. Ex 
vivo methylene blue staining staining of the dissected distal colon.   
 
 We demonstrated the color-fluorescence-polarization endoscope in the CAC model and 
further extended the application towards microscopy to fill the void between fluorescence-
polarization-guided biopsy and H&E staining for validation. Currently, post-biopsy, the tissues 
get processed and stained with hematoxylin and screened by pathologists to ensure complete 
resection. In the case of incomplete resection, the patient is called upon again for a repeat 
surgery, thereby increasing hospitalization time, raising chances of complications arising from 
a second surgery, and increasing healthcare costs. We have developed a fluorescence-
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polarization microscopy method (see Figure 26 for instrumentation setup) utilizing circular 
polarized light to quickly differentiate tumor margins from surrounding uninvolved regions 
such as muscle and subserosa in HT-29 xenograft colorectal cancer tumors implanted in mice. 
This has further been discussed in Chapter 4. 
 
Figure 26. Optical setup for circular polarized light polarization-fluorescence microscopy in HT-
29 post-biopsy tissue assessment 
  
1.6.5 Expansion of targeted NIR Fluorescence probe towards other epithelial-based disease 
models  
Lastly, we expanded the scope of our study to investigate use of targeted-NIR fluorescence 
probe towards early detection of pancreatic cancer. We further developed a platform for: (1) 
non-invasive fluorescence imaging using fluorescence molecular tomography (FMT) to 
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differentiate pancreatitis from pancreatic cancer followed by a (2) guided NIR-fluorescence 
laparoscopy procedure to ensure complete tumor resection. Also, we performed flow 
cytometry to further understand the binding characteristics of the molecular probe and 
conducted immunohistochemistry to compare binding preferences with existing probes for 
pancreatic cancer. Work on this front has resulted in a manuscript that is described in greater 
detail in Chapter 5.   
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Surgical margin identification in colorectal cancer and in-situ validation using 
fluorescence-polarization imaging method 
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Chapter 2 is a reformatted version of a manuscript in submission: “Tauseef Charanya, 
Timothy York, Viktor Gruev, Samuel Achilefu et al. Surgical margin identification in 
colorectal cancer and in-situ validation using fluorescence-polarization imaging 
methods.” Under Dr. Samuel Achilefu’s supervision. My contributions to this work 
included designing the experiments, developing fluorescence-polarization microscopy 
using circular-polarized light, carrying out the imaging studies involving HT-29 
orthotopic implantation and APC min mice, interpreting and analyzing data, and writing 
the manuscript. In this Chapter, I discuss my work in the identification of tumor margins 
in colon cancer models utilizing a NIR targeted probe developed and assessing the 
margins post-biopsy using a rapid, fluorescence-polarization microscopy method with the 
goal of serving as a substitution for gold standard H&E.    
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Abstract  
 
Microscopic tumor cell invasion within the colon is known to complicate complete tumor resection 
and increase the risk of tumor metastasis. When assessing these margins, it is important to 
accurately delineate tumor margins and uninvolved tissues that are possibly infiltrated with tumor 
cells. We have developed a peptide based targeted near infrared (NIR) fluorescent molecular probe 
that can aid in accurate identification of tumor margins for surgical resection in colon cancer. The 
molecular probe was tested in an orthotopic, human derived colon cancer model and a mutant 
mouse model of colon cancer; adenomatous polyposis coli (APC) multiple intestinal neoplasia 
(min). Time-course in-vivo fluorescence imaging conducted using a small animal imaging system, 
along with ex-vivo corroboration studies using the proliferation marker BrdU, demonstrated the 
selectivity of this probe towards proliferating tumor edges. Fluorescence-polarization microscopy 
using circular polarized (CP) light was utilized as a supplementary tool for a quick assessment and 
validation of excised tissue to ensure complete tumor resection and to serve as a rapid 
intraoperative method for examining tumor margins prior to H&E-based pathological diagnosis. 
 
1 Introduction 
As many as 103,000 people are diagnosed with colon cancer every year in the United States and 
around 52,000 patients die of the disease annually, making it the second leading cause of death 
from cancer among adults.1  By convention, staging of colon cancer is based on tumor 
size/invasiveness/histology by tumor node metastasis (TNM) staging. These invasive cancers can 
be completely curable by resection if they remain confined to the wall of the colon: mucosa-
submucosa (T1-2, N0, M0 and T3-4, N0, M0). However, as the tumor invades past the muscle 
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layers and serosa, it spreads to nearby organs (T1-4, N1-2, M0) or to even distant organs (T any, 
N any, M1) through lymph node involvement, making it extremely difficult to resect and leading 
to possible recurrence.2,3 Surgically resected neoplasia using widely accepted endoscopic mucosal 
resection (EMR) technique has yielded recurrence rates as high as 55% in some studies. 4,5 Lymph 
node metastasis with/without organ involvement in N0 is known to have a recurrence of 20%-30% 
and that of 50%-80% in T1-4, N1-2, M0 after surgery.6 Mechanisms for local recurrence include 
and are not restricted to incomplete resection of transmural, mural, or lymphatic disease; tumor 
shedding; and local implantation.7 
It is generally accepted that the colon cancer progression follows a benign adenomatous 
polyp - advanced adenoma – invasive cancer sequence. 8,9 APC mutations have been known to be 
the most common acquired mutation in sporadic colon cancer, occurring in 60% of all tumors. 10 
The most common combination of mutations in the proto-oncogenes involved in the normal-
adenoma-carcinoma progression includes p53 and APC (27.1%).11 Subsequently, two clinically 
relevant models were chosen to best replicate the sequence of mutations for development of early 
adenoma and invasive cancer sequence. An APC min model was chosen to best recapitulate the 
molecular features associated with development of an early adenoma.12 To establish a model for 
invasive colorectal cancer, an HT-29 colorectal cancer cell line (p53 mutant) was used to develop 
a tumor model via orthotopic implantation using a previously established method.13 Together, the 
APC min and the orthotopic HT-29 models serve as ideal models for diagnosis and therapeutic 
efficacies of molecular probes in early and late stages of CRC development. 
Conventional practice dictates diagnosis of colonic polyps to be governed by gold standard 
approaches such as endoscopic polypectomy that rely primarily on the trained eye of the physicians 
performing the procedure.14 When compared to conventional colectomies, it has been shown that 
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laparoscopic methods aid in quality of life for the patient after surgery, although, have failed to 
improve the 5-year survival rate of CRC.15 To improve resection, fluorescence-guided 
interventions emerge as a promising candidate especially when utilizing near infrared (NIR) light. 
Use of NIR light minimizes tissue auto-fluorescence and avoids absorption by hemoglobin (<650 
nm) along with water and lipids (>900 nm), allowing for deeper tissue penetration and imaging. 
Furthermore, it takes advantage of molecular specific features of the diseased state when utilizing 
a molecular probe specific targeted approach.  
With several developments made on the fluorescence-capable laparoscope end, a 
complimentary targeted molecular probe that reliably identifies adenomas in its earlier stage and 
invasive fronts of tumors in later stages with optimum specificity and sensitivity is still lacking. 
Studies utilizing an FDA approved NIR dye, indocyanine green (ICG) to detect tumors have 
demonstrated high background intensity in the subserosa around the tumor, resulting in 
unnecessary follow-up procedures.16  For this reason, interest in developing tumor-specific optical 
contrast agents is rapidly growing. In order to address the shortcomings of surgical intervention 
for improved tumor removal, we report herein (i) a peptide-based integrin-targeting near infrared 
(NIR) fluorescent molecular probe (termed LS301) for CRC margin detection and (ii) subsequent, 
rapid tissue biopsy validation using fluorescence-polarization microscopy. The specificity of this 
molecular probe towards the margins of adenoma (APC min model) and invasive tumors (HT-29) 
was compared to that of a probe with its scrambled peptide sequence analog (termed LS340) via 
time-course in-vivo fluorescence imaging and ex-vivo validation studies using microscopy.  
Furthermore, we extended the scope of the study by incorporating a multi-modal 
microscopy approach that provides both functional and structural information of biopsied tissue. 
The tumor-specific probe reports functional information via fluorescence, whereas polarization 
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imaging reports structural information of the biological tissue of interest via changes in degree of 
linear polarization and angle of polarization. Since muscle tissue is known to have higher 
birefringence due to the increased concentration of collagen fibers, it provides a unique, higher 
polarization signal when compared to the tumor tissue. On the other hand, tumor tissue has been 
shown to have a lower polarization signal compared to surrounding uninvolved tissue as reported 
previously.17 We have further explored the potential of this technique to also identify and 
differentiate tumor tissue from uncompromised submucosal tissue in this study. We have recently 
demonstrated the use of this setup in a mouse mammary carcinoma model where this strategy 
delivers the same vital information as an H&E stain while providing the pathologists and surgeons 
a faster assessment of the tumor- surrounding muscle tissue as there is no staining procedure 
required.18 The study demonstrates the potential feasibility of utilizing the targeted molecular 
probe and post-biopsy fluorescence-polarization validation strategy to assess diverse stages of 
colon cancer. Utilizing the specificity of the molecular probe to guide biopsies via fluorescence 
signature and instantly cross-validating biopsy sections using a dual, stain-free microscopy 
approach is expected to accelerate medical decision, and improve clinical outcomes with minimal 
recall rates.  
2 Methods 
2.1 Near-infrared (NIR) Contrast Agents 
LS301 and its scrambled peptide analog, LS340, were synthesized by our lab by a modification of 
a previously described method.19 In this case, a Gilson HPLC system and the microwave peptide 
synthesizer were used to prepare the peptide and purify the end product. LS301 consists of a near-
infrared fluorescent dye, cypate (780 ex/ 830 em) and a cyclic peptide sequence D-Cys-Gly-Arg-
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Asp-Ser-Pro-Cys-Lys (c(DCGRDSPC)K).  LS340 contains cypate with a scrambled peptide analog 
Lys-Asp-D-Phe-Arg-Gly (c(KDfRG)).20 LS340 was synthesized in a similar way to LS301. The 
conjugation of the dye and peptide sequence was characterized by spectroscopy methods, 
analytical HPLC, and electrospray ionization mass spectrometry. 
 
2.2 Steady-state Optical Measurements 
Absorption spectra were recorded on a DU 640 UV-Visible spectrophotometer (Beckman Coulter, 
Brea, CA), and fluorescence spectra were recorded on a Fluorolog-3 spectrophotometer (Horiba 
Jobin Yvon, Inc., Edison, NJ).  All fluorescence measurements were conducted at room 
temperature and were recorded at excitation of 700 nm and emission scan from 740 to 900 nm. 
 The relative fluorescence quantum yields of the dye were determined using equation 1: 
ΦF(X) = (AS/Ax)(Fx/FS)(nx/ns)2 ΦF(S), 
Equation 1 
where ΦF(X) is the fluorescence quantum yield, A is the absorbance, F is the area under the emission 
curve, n is the refractive index of the solvents used in the measurement and the subscripts s and x 
represent the reference and unknown parameters respectively. Indocyanine green (ICG; Akorn, 
Inc. Decatur, IL) was used as a reference standard, which has a quantum yield of 0.09 in MeOH at 
700 excitation.  
 
2.3 Cell Line 
HT-29 human colon cancer cell line was purchased from the American Type Culture Collection. 
These cells were maintained in Dulbecco's Modified Eagle Medium (DMEM) supplemented, with 
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10% fetal bovine serum (Hyclone). All cells were cultured in a humidified incubator at 370C with 
5% CO2. 
2.4 HT-29 Orthotopic Model 
All animal studies were performed according to protocols approved by at Washington University 
School of Medicine Animal Studies Committee for humane care and use of laboratory animals. 
The orthotopical implantation model has been previously described.13 Briefly, six-week old 
athymic nude mice (NCr- nu/nu; NCI Fredrick National Laboratory) were anesthetized with 
ketamine (85 mg/kg) and xylazine (15 mg/kg) via an intraperitoneal injection (IP) prior to 
performing laparotomy. Isoflurane gas (2% v/v in 100% O2) was delivered via nosecone for 
maintenance of anesthesia throughout the procedure. A 2-3 cm incision was made to expose the 
abdominal cavity and the cecum was identified and exteriorized.  Warm saline was used to keep 
the cecum moist during this procedure. 1 x 106 cells suspended in 50 μL of phosphorus buffered 
saline were injected into the cecal wall from the serosal side. The lack of leakage of fluid from the 
cecal wall and the formation of a visible bulla between the subserosal and submucosal tissue were 
used as an indication of a successful injection. The cecum was returned to abdominal cavity and 
the mouse abdominal wall was closed using a simple running stitch. Mice were evaluated for 
tumors 4-6 weeks post implantation. They were randomly separated in two different groups (n = 
3) for administration of LS301 or LS340. 100ul (in 20%DMSO and 80% saline) of 60 uM of 
imaging agent were injected per mouse via the lateral tail vein. Two hours prior to sacrificing the 
mouse, a thymidine analog, 5-bromo-2-deoxyuridine (BrdU) (Life Technologies, New York, 
USA) was injected intraperitoneally at a volume of 1 ml concentrated reagent per 100 grams of 
body weight.   
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2.5 APC min model 
C57Bl/6J APCmin/+ male mice were obtained from Jackson Laboratory. Mice were fed a 10% fat 
diet (Harlan Teklad) and maintained as approved by Animal Studies Committee of Washington 
University School of Medicine. Six mice were separated in groups of 2; for administration of 
LS301 or LS340. Mice were fasted overnight to minimize fecal matter in their digestive tract and 
minimize interference with time-course fluorescence imaging. 24 hours prior to sacrifice, 100μL 
solution of 60μM concentration of molecular agent was administered intravenously. Once 
sacrificed, the colon was exteriorized, rinsed thoroughly, and imaged using small animal imaging 
system (described below).  Post imaging, colons were carefully cut open and pinned to expose the 
polyps within. Sections were inspected using a Nikon SMZ800 dissection microscope.    
 
2.6 Ex vivo APC min mice imaging 
Colon sections with identified polyps were isolated for further microscopy studies. A clearing 
agent, 50μL glycerol was pipetted onto 8-10 mm of colon tissue sections to allow for microscopy. 
A ZEISS Axioskop 2 MOT microscope with full light capabilities was used to evaluate tissue 
morphology of adenomas and concurrently capture z-stack images of the identified tissue sections 
with polyps. Axiovision image analysis software was used for stacking the z-stack images prior to 
further processing using 3-D reconstruction using Matlab Image Analysis Software. For NIR 
microscopy, an Olympus BX51 upright epifluorescence microscope (Olympus America, Center 
Valley, PA, USA) using 775 +/-50 nm excitation, 810 nm long-pass dichroic, and 845 +/-55 nm 
emission filters was used. 
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2.7 Small Animal Imaging 
The Pearl NIR fluorescence imaging system (LiCor Biosciences, Lincoln, Nebraska) was used to 
perform imaging of live mice, as reported previously.21 Isoflurane gas (2% w/v in 100% O2) was 
delivered via nosecone during the process of imaging nude mice bearing HT-29 tumors. Mice were 
positioned supine on the heated imaging platform. Pre-injection scans were performed to assess 
the autofluorescence signals. A 785 nm excitation wavelength and 830 nm emission was used to 
conduct in vivo imaging. Scans were obtained immediately, 1 hour, 4 hours, and 24 hours post 
administration of imaging agent. Colons exteriorized from APC min mice were placed in a petri 
dish prior to imaging and identifying regions of interest (ROI). For each selected region, the mean 
fluorescence intensity values for tumor and non-tumor tissue were selected and reported for 
analysis. Mean fluorescence intensity was determined for each tissue by ROI analysis and 
combined for each group for statistical analysis. 
 
2.7 Bromodeoxyuridinen (BrdU) labeling and immunohistochemistry 
Each mouse was injected with 1 ml/100g body weight BrdU labeling reagent (Life Technologies, 
New York, USA) intraperitoneally, two hours prior to sacrifice. Once sacrificed, both primary 
tumors from the cecum and secondary tumors from the distal colon were excised and frozen under 
OCT media. Tissues were sectioned in 10-μm thicknesses and used for fluorescence microscopic 
imaging and (Diaminobenzidine (DAB) BrdU staining. For BrdU staining, protocol provided by 
AbCam, Cambridge, USA was utilized while using DAB as the marker and tissues were 
counterstained hematoxylin and eosin.  
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2.8 Histology 
After sacrificing the mice, the tumors were resected along with surrounding cecum and the tissue 
was frozen in OCT. The tissues were sectioned in the cryostat to 10 uM thickness. Slides were 
stained with BrdU antibody and counterstained with Hematoxylin for histological reference using 
a BrdU staining kit (Invitrogen) according to the manufacturer’s protocol.  Briefly, the slides were 
submerged in 3% H2O2 (in methanol) and rinsed with PBS. Slides were incubated with denaturing 
solution, rinsed, blocked with blocking solution and incubated with biotinylated mouse anti-BrdU 
reagent. After washing with PBS, streptavidin-peroxidase reagent was applied to each slide, 
followed by a brief incubation with antibody mixture and counterstaining with hemotoxylin. Slides 
were dehydrated in a graded series of alcohol and mounted with histomount. 
 
2.9 Polarization Microscopy of Invasive HT-29 cancer 
A complementary fluorescence and polarization microscope with division of focal plane (DoFP) 
polarimeter used for this portion of the study was described earlier.18,22 For fluorescence 
microscopy, slides were taken directly from a -80 degree freezer and imaged with an Olympus 
BX51 upright epifluorescence microscope (Olympus America, Center Valley, PA, USA) using 
775 +/-50 nm excitation, 810 nm longpass dichroic, and 845 +/-55 nm emission filters. For 
polarization microscopy, a DoFP sensor was utilized which uses a CCD monolithically integrated 
with aluminum nanowire polarization filters. The imaging array was arranged in blocks of four 
(two-by-two) superpixels. Each superpixel consists of four pixels that are composed of nano-wire 
polarization filters with the transmission axis oriented at 00, 450, 900, and 1350. These nanowires 
are 70 nm wide, 140 nm tall, and spaced 140 nm from center to center. A detailed description of 
the fabrication procedure these polarization filters has been described before.22 The raw data 
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obtained from the DoFP sensor is first calibrated 23 and interpolated 24 to obtain accurate and high 
spatial resolution polarization information about the imaged tissue.   
 Input circularly polarized light was generated by the combination of a achromatic quarter 
wave plate (Thorlabs AQWP05M-600) and a linear polarizer (Newport 10LPVISB), both designed 
for use in the visible (400nm to 700nm) spectrum.  The quarter wave plate was aligned at 45 
degrees with respect to the linear polarizer on a precision rotational stage.  The circular polarizer 
was placed after the broadband illumination and transmitted through the sample.  Using a Division-
of-Focal-Plane polarimeter, the angle of polarization (AOP) and Degree of linear polarization 
(DoLP) was then measured for the sample. The DoLP is related to the retardance of the tissue 
while the AOP provides information in regards to the orientation of the muscle fiber.  
 
2.10 Statistical Analysis 
All data values are represented as mean  SEM. A two-sided pairwise t test was applied for 
analysis. P values of <0.05 were considered statistically significant.  
3 Results 
3.1  Characterization of targeted molecular probes 
We have made use of the unique ability of NIR light to image deeper in the tissue by conjugating 
the reporter molecule (cypate) to a targeting moiety comprising of peptide sequence D-(Cys-Gly-
Arg-Asp-Ser-Pro-Cys-Lys conjugated to NIR dye, cypate (LS301). We have previously reported 
on the ability of this molecular probe to selectively accumulate in tumors as compared to 
surrounding tissues.21 We further explored the specificity of the molecular probe towards a tumor-
62 
 
front and tumor core and compared it with a negative control, scrambled peptide sequence (Lys-
Asp-D-Phe-Arg-Gly) conjugated to cypate (LS340). In this process, we ensured the maintenance 
in size and hydrophobicity of the two compounds. A detailed description of the synthesis of such 
cypate based molecular probes has been reported earlier.19 The chemical structure of both probes 
is shown in Fig. 1a and 1b. Their excitation and emission characteristics have been reported in Fig. 
1c and 1d. Furthermore, we tested the quantum yield of both compounds with FDA approved NIR 
agent, indocardiogreen (ICG) in two different solutions; dimethyl sulfoxide (DMSO) and 
phosphate buffered saline with 1% bovine serum albumin (PBS/BSA) as illustrated in Fig. 1e. 1% 
BSA in PBS was utilized due to its ability to replicate a similar environment in solution as that of 
serum in vivo.25 Both physical and chemical characteristics of the probe hint at the similarities that 
exist with current, FDA approved dye. 
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Figure 1. Physical and chemical characteristics of molecular probes, LS301 and LS340. (A) Chemical structure of 
LS301 (c(DCGRDSPC)K) and (B) LS340 (c(KDfRG)). Normalized absorption and emission spectra of (C) LS301 
and (D) LS340. (E) Table detailing quantum yield of LS301, LS340 and FDA approved indocyanine green (ICG) 
dissolved in both dimethyl sulfoxide (DMSO) and phosphate buffered saline with bovine serum albumin (BSA).  
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3.2 Efficacy study in orthotopic colorectal cancer (HT-29) and APC min models  
An orthotopic HT-29 colorectal cancer (CRC) model was first employed to compare the efficacy 
of the molecular probe in an advanced colorectal carcinoma model.  Dosing of molecular probes 
was pre-established in study report previously21 as 0.3mg/kg. Post administration, PearlCam 
software was used to analyze the images taken and report fluorescence intensity in arbitrary values. 
Values were normalized for both compounds over a 24-hour time period for in vivo and ex vivo 
imaging. Fig. 2a demonstrates the time-course fluorescence imaging using the NIR fluorescent 
probe LS301. It is able to highlight the ability of LS301 to maintain good tumor localization, with 
high contrast between the primary tumor and surrounding regions at 4 and 24 hours post 
administration.  In contrast, LS340 demonstrated a very short-lived accumulation in the primary 
tumor at 4-hr time point and cleared via the primary clearance organ for hydrophobic dyes, the 
liver, by 24 hours. In order to quantify the dye retention in tumors via fluorescence signal, mean 
signal-to-noise ratio (SNR) was computed over time in regions identified as primary tumor based 
on site of administration and post-sacrifice primary tumor location verification. Using equation 2, 
the SNR computed demonstrated greater than five-fold retention of LS301 in primary tumor when 
compared to its scrambled peptide counterpart, LS340 at 24 hours as shown in Fig. 2b. 
 
Mean SNR =  
Total intensity from tumor 
  Area of ROI containing tumor  −    
Total background intenisty
Area of ROI containing background
Standard Deviation of background intensity
 
 
Equation 2 
 
Furthermore, in 30% of the mice, the palpable tumor region was known to extend further to 
what was later identified as, a secondary, smaller, non-palpable, locally metastasized tumor in the 
distal colon. The region encompassing secondary tumors was identified and corresponding 
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fluorescence values were recorded at different time points and compared with fluorescence 
originating from surrounding uninvolved region to provide tumor-to-background ratios in mice 
treated with LS301 or LS340, as shown in Fig. 2b. A tumor-to-background ratio (TBR) of 4.5 was 
observed for primary tumors and that of 3 for secondary tumors in mice administered with LS301. 
Conversely, a TBR of 0.8 was observed for primary tumors and that of 0.95 for secondary tumors 
in mice administered with LS340.   
 
Figure 2. Time course fluorescence imaging in orthotopic HT-29 colorectal cancer model. (A) Images in the top row 
depict mice treated with LS301 and bottom row that with LS340.  Both palpable and non-palpable tumors identified 
post-sacrifice are marked by a red dotted line. NIR fluorescence Images were acquired with the 800 nm channel over 
time (0 hr, 1hr, 4 hours, and 24 hours) after administration of 6 nanomoles of LS301 or LS340 solution. 24 hours post 
administration, animals were euthanized and tumors within the cecum along with locally invaded tumors along the 
distal colon (not palpable) were exteriorized and imaged ex vivo. (B) Mean signal to noise ratio (SNR) measured over 
time. Mean background intensity of the region of interest marking the exteriorized, visible tumors was compared to 
that of another region of interest in the same mouse marking surrounding uninvolved tissue and muscle. Error bars 
represent 95% confidence interval.   
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Figure 3. Time course fluorescence imaging in APC min model. (A) Images in the top row depict mice treated with 
LS301 and bottom row that with LS340. NIR fluorescence Images were acquired with the 800 nm channel over time 
(0 hr, 1hr, 4 hours, and 24 hours) after administration of 6 nanomoles of LS301 or LS340 solution. 24 hours post 
administration, animals were euthanized and the small and large bowel were exteriorized. Visible polyps were 
identified and later verified by microscopy. Polyps identified in the small and large bowel are both marked by a dotted 
red circle. (B) Mean fluorescence intensities for both LS301 and LS340 in regions identified as polyps was compared 
to surrounding uninvolved regions to provide Mean SNR values. Error bars represent 95% confidence interval.  
 
  
Similarly, a time-course fluorescence imaging was conducted on APC min model as shown in 
Fig. 3a.  Due to the presence of a significant number of <3mm polyps in the stomach and small 
bowel, a higher fluorescence intensity is observed in these regions with LS301 versus LS340, due 
to enhanced selectivity. A mean SNR of 3.38 ± 0.7 was observed with mice treated with LS301 as 
compared to 0.3 ± 0.15. To further confirm the presence of polyps, colonic segments were isolated 
based on regions exhibiting higher fluorescence and the presence/absence of polyps was later 
verified by ex vivo tissue microscopy studies as shown in Fig. 4a. SNR were obtained of regions 
identifying adenomas (later verified) and surrounding uninvolved colon tissue. Consistent with the 
ability of LS301 to demarcate the boundaries of the advanced staged tumors as in HT-29, Figure 
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4b presents a mean SNR of 45 ± 7.2 using LS301 as opposed to 3 ±  1.8 using LS340 amongst 
polyps arising in APC min model. Enhanced SNR and TBR ratios using LS301 in both HT-29 and 
APC min reaffirmed the specificity arising from GRD based targeting sequence in LS301.  
 
 
 
Figure 4. Ex vivo brightfield and fluorescence microscopy of polyps in APC min model using LS301 and LS340. 
(A) Boundaries of identified polyps are marked by a dotted red line in the brightfield image and corresponding NIR 
fluorescence images are presented alongside. (B) Mean signal intensities of regions identified and verified as polyps 
are compared to those of surrounding uninvolved regions.  
 
 
3.3 Ex vivo fluorescence microscopy and corroboration with proliferation marker 
To further investigate the binding preference of the molecular probes within tumor 
microenvironment, two primary regions within the tumor were selected; tumor core and 
boundaries. Regions with similar morphology within tumors treated with LS301 and LS340 were 
compared to identify differences in binding patterns between both molecular probes. BrdU, marker 
widely known to identify proliferative regions, was used as a standard for corroborating NIR 
fluorescence binding patters. When compared to LS340, the binding pattern of LS301 corroborated 
extremely well with BrdU, in both; tumor core as shown in Fig. 5a, and tumor-uninvolved 
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boundary, as shown in Fig. 5b. LS 301 localized to the edges of the tumor making it a potential 
tool for assessing tumor margins during tumor resection.  
 
 
Figure 5. Comparing binding specificity of LS301 and LS340 with proliferation marker, BrdU (Dab counterstain) in 
HT29 tumor core and invasive boundaries. (A) H&E, BrdU counterstained with hematoxylin and NIR fluorescence 
image of tumor core region using LS301 and LS340. (B) H&E, BrdU counterstained with hematoxylin and NIR 
fluorescence image of tumor boundary using LS301 and LS340.  
 
 
3.4 Using circular polarized (CP) light for polarization microscopy 
 Targeted fluorescence guided surgery utilizing molecular beacons that identify invasive 
tumor fronts is a strong first step towards diagnosis. To ensure complete resection, polarization 
and fluorescence microscopy were used in conjunction. A simple system of linear polarizer and 
quarter wave retarder was developed to convert the incident unpolarized light to circularly 
polarized (CP) incident light. Current methods utilize a specialized stage that consists of a 360 
degree rotating specimen stage to facilitate orientation studies with centration of the objectives and 
stage with microscope optical axis to allow for center of rotation to coincide with the center of the 
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field of view. However, this system configuration does not allow for a real-time assessment of the 
tissue. We circumvented these challenges by developing an imaging configuration and sensor 
setup capable of reporting DoLP and AOP changes in the transmitted light. 
Briefly, CP light that gets transmitted through a birefringent object, becomes elliptically 
polarized on the output where the ellipticity is directly dependent on how birefringent the tissue 
under investigation is. The more birefringent muscularis mucosa and subserosa regions alter the 
polarization state of light to a more linearly polarized state. Both; the Angle of Polarization (AOP) 
and Degree of Linear Polarization (DoLP), present varying information regarding the polarization 
state of transmitted light through the tissue. With incident CP light, the transmitted AOP reports 
the alignment of the dominant birefingent axis in the tissue.  On the contrary, dense, tumor tissue 
has a two-fold effect on the polarization state of light.  Firstly, the tumor tissue lacks birefringence, 
causing predominantly circularly polarized light transmitted through the tissue, causing a lack of 
detected light with a high degree of linear. Furthermore, the tumor tissue possesses differential 
properties such as greater radius and density of nuclei, higher absorption coefficients and higher 
order of back scattering of light26,27 when compared to surrounding uninvolved tissue, contributing 
to a lower DoLP signature and a higher contrast with surrounding uninvolved tissue.  
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Figure 6. Polarization-Fluorescence microscopy of tumor core and tumor boundary in HT-29 orthotopic model. (A) 
BF image of tumor core alongside corresponding DoLP and AOP images using circularly polarized incident light. The 
same region is identified for NIR fluorescence and verified by H&E. (B) BF image of tumor boundary alongside 
corresponding DoLP and AOP images using circularly polarized incident light. The same region is identified for NIR 
fluorescence and verified by H&E. Tumor boundary inset illustrates the region at a lower magnification. (C) Mean 
DoLP values computed by selecting three different regions – tumor core, tumor at the boundary and surrounding 
uninvolved tissue. Statistically significant mean DoLP values obtained with p<0.005  
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3.5 Fluorescence-Polarization Microscopy of invasive HT-29 tumor front using incident 
circularly polarized light  
Fluorescence microscopy was used as a first level assessment tool to identify the tumorous regions 
based on NIR readout sensitive to molecular-level based sensitivity. Polarization microscopy 
served as a label free, validation technique to present structural information needed to provide 
physical context to NIR image and to serve as an additional contrast tool based on tissue 
composition and orientation. Polarization data was captured in real-time in the form of two 
readouts; degree of linear polarization (DoLP) and angle of polarization (AOP). Readouts obtained 
for both tumor core and tumor-uninvolved surrounding tissue boundaries are presented in Figures 
6a and 6b. Furthermore, corresponding NIR readouts of the same region are also presented to 
accentuate the complimentary nature of both modalities. Lack of morphological information 
provided by NIR image in Fig. 6b is compensated for by the DoLP and AOP image, as shown by 
its ability to identify birefringent muscle tissue and thereby provide morphological context. 
Regions identified by fluorescence-polarization microscopy were verified by histology via gold-
standard H&E stain and presented in Figure 6a and 6b. Mean DoLP values were computed and are 
shown in Figure 6c. The core and the invading front of the tumor had similar mean DoLP values 
of 0.2603 +/- 0.0625 and 0.2715 +/- 0.0961. In comparison, surrounding uninvolved regions had 
mean DoLP values of 0.5959 +/- 0.0524. Due to lack of change in structural orientation of tissue 
composition, there was no change observed in AOP for tumor core. As for the tumor boundary 
and surrounding uninvolved tissue, presence of birefringent muscle fibers oriented normal to the 
tumor, resulted in a strong contrast. This method demonstrated its potential of serving as a 
definitive tool for distinguishing structural features that are non-tumor like in a label-free, real-
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time fashion and complement molecular-sensitive information, obtained via a fluorescence 
readout. 
4 Discussion 
We have developed a targeted molecular probe to specifically identify invasive tumors fronts for 
improved tumor resection and an imaging strategy that would help validate complete tumor 
removal. Unlike current targeted-imaging approaches to interrogate molecular and structural 
signatures of CRC, the combined fluorescence and polarization contrasts create a new paradigm 
for identifying colonic lesions with high accuracy. An APC min model was chosen to best 
recapitulate the molecular features associated with development of an early adenoma while an 
orthotopic HT-29 colorectal cancer tumor model was used to best replicate an invasive cancer. The 
nature of the orthotopic implantation procedure, allows the tumor to start growing from the cecal 
wall and penetrate deeper into the serosa, helping us to better identify and report the invasion 
process. Optical imaging has already proven itself as a reporting strategy in the form of clinical 
endoscopy, laparoscopy amongst other constantly emerging optical-based methods including 
confocal laser endomicroscopy, utilizing targeted molecular imaging.28 
Targeted-molecular imaging efforts to specifically identify polyps have come in the form of 
using a Cy 5.5 conjugated cathepsin B to identify polyps in APC mice29 or even topically applying 
fluorescein conjugated peptide sequence (VRPMPLQ) to identify dysplastic mucosa.28 However, 
such agents are limited by their shallow tissue penetration and their lack of specificity towards 
invading tumor boundaries, which limit their usefulness for guiding surgical resection. Use of NIR 
molecular probes bridges this gap by allowing for imaging through deeper tissue penetration while 
maintaining sensitivity. Furthermore, while efforts in this area over the last decade have been on 
identifying dysplastic lesions and polyps, there has been a lack of effort in developing probes 
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capable of specifically reporting invading tumor margins that have perforated deeper into the 
tissue.28,29 We have utilized the unique ability of our targeted molecular probe LS301 to target 
invasive fronts of tumor specifically with high specificity and sensitivity in early and late stage 
colon cancer models.  
Provided the application of invasive margin detection for improved resection, topical 
administration approach that is generally taken for improved visualization in colonoscopy 
screenings is deemed unsatisfactory due to insufficient penetration through the tumor mass. In 
order to capture the infiltrated tumor cells in the subserosa, past the initial mucosal boundary, an 
intravenous delivery approach was chosen. Time-course NIR fluorescence study highlighted the 
ability of LS301 to capture early adenomas as shown in Figure 3a, along with primary and 
secondary, locally invaded tumors, as presented in Figure 2a with preferential binding over its 
surroundings. This was evident by TBR values of 4.5 and 3 for primary and secondary tumors and 
that of 3.25 for polyps.  Its counterpart, LS340 (scrambled peptide analog) demonstrated no such 
retention and selective localization within the tumors or polyps as shown in Figure 2a and Figure 
3a. The specificity of targeting moiety in LS301 is highlighted, when comparing its binding 
preferences to that of, scrambled peptide counterpart, LS340.  
Consistent with in-vivo findings, examination of ex-vivo tissue demonstrated the enhanced 
ability of LS301 to bind to tumor edges, which are reportedly proliferative in nature. To further 
validate our claim, we compared the binding preference of LS301 with BrdU. As a structural 
analog of thymidine, BrdU can get incorporated in the DNA during the synthesis phase of the cell 
cycle as a uridine derivative, thereby serving as a proliferation marker. By comparing various 
tumor tissue morphologies and surrounding uninvolved regions as shown in Figure 5b, LS301 
emerges as a strong candidate for detecting the proliferating regions of the tumor with 100% 
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sensitivity and specificity. Furthermore, unlike existing molecular probes that are confined to 
identify only specific stages of tumorigenesis, LS301 offers the ability to determine multiple stages 
of cancer development. By demonstrating preferential binding towards proliferative regions within 
the tumor, LS301 has high potential to improve the management of colorectal cancer, by guiding 
complete tumor resection. 
In order to resect the tumor completely, it is important for the surgeon to be able to judge the 
stage of the tumor, which is classified by the level of invasion. As tumors surpass the mucosa and 
submucosal layers towards the muscle and serosa (T1-4, N1-2, M0), it gets very close to spreading 
to nearby organs via lymph node involvement. With the HT-29 orthotopic model, we were able to 
simulate a T3-4, N0, M0 colorectal cancer type of tumor invasion. For a label free, quick 
assessment of resected tumor tissue, and to satisfy the diagnosis provided by a pathologist via 
H&E staining, there is a need to identify both, molecular and structural specific features. While 
LS301 has immense potential to satisfy the needs from molecular front, polarization imaging has 
the ability to provide this information reliably from the structural front. Ability of CP light to detect 
birefringence in samples under investigation was employed towards tumor boundary assessment 
using a polarization-sensitive imager. While readout AOP reports specifically on the orientation 
of birefringent tissue under investigation such as collagen fibers and muscle sarcomeres, DoLP 
reports on the fraction of transmitted light that is linearly polarized due to birefringence in the 
tissue. We have previously reported differences in DoLP signature in cancerous and surrounding 
uninvolved tissue using a similar polarization-sensitive imager coupled to an endoscope.17 
Cancerous tissue possesses distinct morphological features, such as increased nuclear size and 
increased nuclear/cytoplasmic ratio, which results in significant multiply scattered components of 
light and a corresponding decrease in DoLP signature. A mean DoLP ratio of 2.3 fold was observed 
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between cancerous and surrounding uninvolved tissues as shown in Figure 6c. The exceptionally 
high DoLP signal in surrounding uninvolved tissue stems from the formation of firmly matted 
fibrotic bands within the serosa and mesentery and the increase in concentration of linearly 
birefringent material such as actin. We demonstrated our ability to rapidly interrogate regions of 
interest in real time (at 40 frames per second) using this method. 
The combination of an invasive tumor front-targeting molecular probe that has the potential to 
be easily integrated with a NIR-capable endoscope and the development of a microscopy based 
fluorescence-polarization tumor-boundary assessment strategy, provides a new paradigm for 
accurate complete resection of colorectal cancer. While NIR-based fluorescence endoscopy could 
serve as a strong first line of defense, polarization-fluorescence microscopy, in conjunction, has 
potential to verify and validate complete resection prior to a lengthy H&E staining and diagnosis 
process. The system and method described in this study are applicable to the assessment of other 
pathologic conditions, such as upper GI lesions, and melanoma. 
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Chapter 3 
Intravenous, topical and oral administration routes for targeted molecular probe in colon 
cancer  
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Chapter 3 is primarily based on the administration routes that were explored utilizing the 
targeted molecular probe identified in Chapter 2. Under Dr. Samuel Achilefu’s 
supervision, the routes that were explored include intravenous, a novel topical 
administration strategy and oral gavage. My contributions to this work included designing 
the experiments, developing the novel topical administration approach, carrying out the 
imaging studies involving the various administration routes, interpreting and analyzing 
data, and writing the manuscript. In this chapter, I discuss my work on the efficacy of 
administration strategies in identifying tumor along with the advantages and 
disadvantages associated with the various approaches. The chapter begins discussing the 
(i) intravenous approach, (ii) topical sol-gel approach, and (iii) oral gavage approach 
along with the shortcomings associated with each of them. 
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The effectiveness of contrast agents in probing molecular processes and functions in the cell 
depend on their efficiency of delivery to target tissues. Delivery of optical probes to the tissues 
have been known to be dictated by nonspecific mechanisms1-4, specific mechanisms as well as 
nonspecific-followed by a secondary activated mechanism5,6.  
 As for non-specific delivery, molecular probes primarily rely on differential 
accumulation of the probe in pathological tissue based on disrupted tissue capillary permeability 
or other structural aberrations. The retention of non-specific contrast agents in tumor is usually 
restricted in the cases of advanced tumor stages. Indocyanine green (ICG) has been shown in 
several occasions to be used as a blood-pool agent by imaging tumor vasculature in tumor 
xenografts7, however it has been shown that ICG demonstrates sporadic uptake in different 
tumor xenografts, thereby making it a non-specific contrast agent4.  Generally speaking, the low 
specificity and sensitivity of nonspecific optical contrast agent such as ICG limit their use as 
blood-pool agents for optical imaging of tumors. 
 Site-specific delivery mechanism takes advantage of optical molecular probes that can 
incorporate essential features of tumor pathogenesis to induce specific response in tumors. This 
takes advantage of specific characteristics of the tumor such as up-regulation of factors specific 
to tumor allowing to deliver contrast agent to specific target. Some characteristics that can be 
used for specific delivery include overexpressed receptors on tumor cell membranes, adhesion 
factors during angiogenesis, and tissue-specific markers for cancer to name a few. To achieve 
this, several carriers can be used including macromolecules, peptides, antibodies, and proteins 
that can mediate delivery of optical probes to tumors.  
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1. Intravenous approach 
 The peptide-based targeted molecular probe that has be identified by Achilefu et al.8 
makes an excellent blood-pool agent allowing for optimal tumor to muscle ratio at the 24-hour 
time point when injected intravenously. In order to demonstrate efficacy of the molecular probe 
towards colon cancer application using the intravenous, we developed an orthotopic HT-29 
orthotopic model and utilize a spontaneous APC min model of colon cancer.  
 
 
Figure 1. LS301 efficacy in HT-29 orthotopic model (top) and APC min model (bottom) via 
intravenous administration approach.  
 
The intravenous approach demonstrated enhanced tumor-to-background ratio in both 
models 24 hours post administration when using a planar imaging system with high sensitivity. 
This served as an impetus to test intravenous approach in a more invasive, endoscopy setting for 
colitis-associated cancer. We developed an azoxymethane-dextran sodium sulfate (AOM-DSS) 
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model that best recapitulates colitis-associated cancer sequence. A NIR capable endoscope was 
developed (Figure 2) for carrying out endoscopy on AOM-DSS treated mice. Mice were 
administered with six nanomoles of LS301 24 hours prior to the procedure to provide optimal 
contrast. 
 
Figure 2. Endoscope setup used for color-fluorescence-polarization imaging of CAC lesions. 
The setup is fixed on a tripod to allow for minimal movements while switching modes. NIR 
Fluorescence mode requires a 780 nm excitation source and a NIR sensitive sensor at the distal 
end of the endoscope to capture images. Polarization mode requires a white light source and a 
polarization capable sensor that is discussed further in Chapter 4.  
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Figure 3. NIR endoscopy in AOM-DSS model captured at 5 frames per second. Tumor and 
surrounding uninvolved tissue are identified in both color (left) and NIR (right) images. Note that 
breathing artifacts integrated over five seconds result in imperfect co-registration. 
 
LS301 demonstrated retention in the tumor with a tumor-to-background ratio (TBR) of 
3.2 ± 0.4 as shown in Figure 3. The high integration time is attributed to utilizing a NIR sensitive 
camera that only has a quantum efficiency of 25% at 800 nm and using a light source that allows 
less than 5 mW/cm2 of incident light at 780 nm. In order to demonstrate the real-time capability 
of the NIR endoscope system, we utilized a Karl Storz SPIES ICG system. The endoscope 
operates in color, auto fluorescence and NIR modes allowing for seamless transition between the 
modes. It provides 1920 x 1080 HD resolution scan with integrated parfocal zoom lens (focal 
length f = 15-31 mm). The three-chip camera head allows seamless integration of the three 
modes offered with the ability to provide HD resolution images. Furthermore, the D-light source 
developed by Karl Storz allows different excitations for color, autofluorescence and NIR modes. 
Excitation light in the NIR mode was however > 30 mW/cm2 (over six fold greater than FDA 
84 
 
allowance for human use). Figure 4 presents the fluorescence spectra of the excitation source in 
various modes.  
   
Figure 4. Fluorescence spectra in autofluorescence (blue), white (grey) and NIR (orange) modes. 
 
 The Karl Storz SPIES system was applied towards a subcutaneous prostate cancer model 
generated by implanting 10 million PNEC cells in the hind limb of the mouse. The tumor was 
allowed to grow for a week to form a small mass of 0.5 mm prior to imaging using the system. A 
simple skin-flap technique in the region of interest was sufficient to expose the hind limb site of 
implantation. Images were obtained in color and NIR modes where the two modes were swapped 
via a easy-to-use toggle switch. NIR images obtained provided an impressive TBR of 6.2 ± 1.2 
as shown in Figure 4.   
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Figure 4. Real-time NIR endoscopy in subcutaneous prostate cancer model using Karl-Storz 
SPIES system 
 
 For detection of precancerous and cancerous lesions in CAC and SCC, the lesions are 
extremely small in size <0.5 mm usually and the probe accumulation in tumors is fairly minimal 
in volume and concentration (< 1 µM). Although the contrast between tumor and background is 
high, in order to do real-time NIR endoscopy, there is a need for a system with high detection 
sensitivity, high quantum efficiency sensor in the NIR regime and a powerful light source to 
illuminate with sufficient number of photons to withstand the transmission losses from within the 
rigid optics of the endoscope.  
While the intravenous approach takes the greatest advantage of the dynamics associated 
blood-pool contrast agents, it does have some downsides. Intravenous administration of molecular 
probes leads to distribution in all organs in the body, making toxicity of the molecular probe a 
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valid concern. Furthermore, 24 hours for optimal contrast, would require the patient to come into 
the clinic a day before the procedure, increasing healthcare costs in the process.   
 
2.  Topical administration approach 
 With translatability in mind for colonscopy application, we explored the topical 
administration strategy. The inclusion of topical administration approach such as in the case of 
chromoendoscopy (CE) for diagnosis of lesions in ulcerative colitis has been widely debated9. CE 
using methylene blue has demonstrate potential in being able to identify pit patterns that are 
typically associated with low and high grade dysplasia10.  
 We first explored the topical administration approach using LS301 on various stages of 
AOM-DSS induced colorectal cancer. Frozen tissue sections obtained from resected tumors were 
incubated with LS301 for an hour prior to being washed three times by PBS and imaged. Both 
carcinoma and dysplastic stages in CAC were investigated.  
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Figure 5. Ex vivo NIR fluorescence and corresponding H&E imaging of cancerous tissue from 
AOM-DSS model 
 
Figure 5. Ex vivo NIR fluorescence and corresponding H&E imaging of dysplastic tissue from 
AOM-DSS model 
  
 Preferential uptake of LS301 is observed in both dysplastic and cancerous tissues when 
compared to surrounding uninvolved tissue. Based on the selective uptake, we administered a 
formulation similar to intravenous administration described previously, topically. 60µM 
formulation of LS301 in PBS was injected via the instrument channel of the endoscope in the distal 
colon during an endoscopy procedure and post three washes, color and NIR imaging was 
conducted. Images obtained provided uneven uptake of LS301 throughout the colon and low NIR 
signal overall possibly due to two reasons; uneven distribution of LS301 sprayed on, and lack of 
“incubation time” with tissues which would allow for internalization and retention of LS301 in 
precancerous and cancerous tissues as shown in intravenous approach.  
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 There was a clear need for an administration strategy that allowed even distribution of 
administered molecular probe and ample “incubation time” with all the surrounding tissue due to 
the serendipity associated with flat lesions. To address these concerns, we employed a sol-gel 
approach that allows the LS301 formulation to stay liquid at under a critical transition temperature 
and turn into a gel at room temperature or higher. Furthermore, in order to flush out the formulation 
from the colon post-incubation, we took advantage of its reversible nature of the sol-gel by flushing 
the colon with cold PBS, thereby allowing for the gel to transition back to liquid and exit the colon. 
Figure 6 demonstrates the overall process of topical administration that was used and Figure 7 
demonstrates results obtained via this method in AOM-DSS model. 
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Figure 6. Topical administration strategy for colonscopy on live AOM-DSS treated mice. 1) 
Briefly a 25% w/v formulation of Poloxamer f127 (Sigma Aldrich, St. Louis) was used to dissolve 
60uM LS301 solution and kept on ice at 40C to maintain liquid state prior to administering. 2) 
Solution was administered via instrument channel and allowed to incubate for ten minutes. 3) Cold 
PBS was used to flush the distal colon three times in order to reverse the phase of sol-gel 
formulation and wash out of colon prior to imaging. 
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Figure 7. In vivo color-NIR endoscopy in AOM-DSS model of adenomatous tumor (top) and (flat 
lesion identified) and later verified via H&E (Chapter 4).  
  
 
 In vivo topical administration of sol-gel formulation provided a high contrast to noise ratio 
(CNR) in adenomatous tumors (20.6±1.65) and flat lesions (12.1±1.03) versus surrounding 
uninvolved colon tissue versus CNR of inflamed tissues (1.62±0.41). However, the sol-gel topical 
administration approach has its own limitations when considering translatability. The low 
transition temperature of 200C requires cold PBS (<150C) flushes to reverse the temperature and 
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allow for exit from the colon potentially resulting in great discomfort to the patient. That said, the 
sol-gel method allows us to fine tune the transition temperature based on the concentration of 
Pluronic f-127 used as shown in Figure 8. Furthermore, due to its viscous nature, the incubation 
time required could exceed that of a formulation composed of LS301 and PBS. Also, the topical 
administration approach has been known to increase the procedure time considerably given the 
need to repeatedly spray the formulation as the endoscopist moves along the colon in search for 
precancerous and cancerous lesions. 
 
Figure 8. Transition temperature versus concentration relationship of pluronic F-127 (adapted 
from Lee et al.11 
 
 
 
 
 
 
92 
 
3. Oral gavage administration  
 
The goal of exploring the oral gavage administration approach was to allow for a faster 
colonscopy procedure (major shortcoming of topical administration) while allowing for 
minimal change in routine colonscopy preparation. The formulation employed would be fairly 
easy-to-use as it could be simply incorporated into the dye mixture in the enema solution prior 
to the procedure. Also, compared to the intravenous approach, the oral gavage approach is 
semi-targeted, restricting the probe distribution strictly to the digestive system.  
  In order to test this approach, we developed an orthotopic colon cancer model by injecting 
500,000 Ht-29 tumor cells in the cecal wall of nude mice. The tumors were allowed to grow 
for two weeks to give us a small lesion. The diet is altered in these mice to increase the 
likelihood of fecal matter-free colon and provide minimal obstruction for the administered dye 
to interact with the tissue. Figure 9 shows a general schematic explaining the timing of dietary 
changes introduced during the procedure. We administered 120 µM of LS301 orally using a 
gavage syringe and imaged the mice over a 72 hour period to test clearance prior to sacrificing 
the mice and exteriorizing the intestine and cecum. Figure 10 shows a general schematic 
explaining the different time points the mice were imaged in relation to the diet. 
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Figure 9. Diet pattern followed prior to and after the administration of LS301 
 
Figure 10.  Administration and imaging time points post administration 
 
 Mice (with no tumors) were used as controls for this experiment and were imaged over a 
course of 72 hours prior to exteriorizing the cecum and imaging the inoculated sites as shown 
in Figures 11 and 12.  
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Figure 11. In vivo imaging in control (no-tumor) mice over 72 hours. Cecum is exteriorized    
72 hours post administration and associated fluorescence intensity was examined. 
 
Figure 12. In vivo imaging in tumor mice over 72 hours. Cecum is exteriorized 72 hours post 
administration and associated fluorescence intensity was examined. 
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 The implantation sites of tumor demonstrate an enhanced LS301 uptake as shown by the 
arrows in Figure 12. Furthermore, to ensure the LS301 distribution stays restricted to the digestive 
tract, we conducted a biodistribution study post-sacrifice where we measured the fluorescence 
intensity associated with various organs in the body such as skin, muscle, brain, blood, heart, lungs, 
spleen, kidney and liver (as shown in Figure 13).  
 
Figure 13. A bio-distribution study 72 hours post administration demonstrating clearance of 
LS301 from all the major organs 
  
Although we observed enhanced specificity towards tumor in the cecum, we further 
validated stability of our peptide-based molecular probe under different pH conditions that it 
would be subjected to while passing through the stomach. Figure 14 demonstrates stability 
results of LS301 obtained under three different conditions, pH = 1.0, 4.0, and 7.4.  
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Figure 14. pH stability test of LS301 over time 
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Chapter 4 
Trimodal color-fluorescence-polarization endoscopy aided by a tumor selective molecular 
probe accurately detects flat lesions in colitis-associated cancer 
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Chapter 4 is a reformatted version of a published manuscript: “Tauseef Charanya, Timothy York, 
Viktor Gruev, Samuel Achilefu et al. Trimodal color-fluorescence-polarization endoscopy aided 
by a tumor selective molecular probe accurately detects flat lesions in colitis-associated cancer.” 
Under Dr. Samuel Achilefu’s supervision, my contributions to this work included designing the 
experiments, developing fluorescence-polarization endoscope, carrying out the imaging studies 
involving AOM-DSS model, interpreting and analyzing data, and writing the manuscript. In this 
Chapter, I discuss my work in the development of a fluorescent-polarization endoscope for 
identification of flat and adenomatous tumors in a CAC murine model utilizing a NIR targeted 
probe.  
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Abstract  
Colitis-associated cancer (CAC) arises from premalignant flat lesions of the colon, which are 
difficult to detect with current endoscopic screening approaches. We have developed a 
complementary fluorescence and polarization reporting strategy that combines the unique 
biochemical and physical properties of dysplasia and cancer for real time detection of these lesions. 
Using azoxymethane-dextran sodium sulfate (AOM-DSS) treated mice, which recapitulates 
human CAC and dysplasia, we show that an octapeptide labeled with a near infrared (NIR) 
fluorescent dye selectively identified all precancerous and cancerous lesions. A new 
thermoresponsive sol-gel formulation allowed topical application of the molecular probe during 
endoscopy. This method yielded high contrast-to-noise ratios (CNR) between adenomatous tumors 
(20.6±1.65) and flat lesions (12.1±1.03) and surrounding uninvolved colon tissue versus CNR of 
inflamed tissues (1.62±0.41). Incorporation of nanowire-filtered polarization imaging into NIR 
fluorescence endoscopy shows high depolarization contrast in both adenomatous tumors and flat 
lesions in CAC, reflecting compromised structural integrity of these tissues. Together, the real-
time polarization imaging provides real-time validation of suspicious colon tissue highlighted by 
molecular fluorescence endoscopy. 
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1 Introduction 
Inflammatory Bowel Diseases (IBDs) consist of ulcerative colitis and Crohn’s disease, which are 
characterized by uncontrolled inflammation of the gastrointestinal tract in genetically susceptible 
individuals exposed to environmental risk factors.1 The incidence and prevalence of IBD has 
increased in recent years, affecting 1.4 million Americans in 2012 alone.2 Moreover, peak onset 
of this disease occurs in the second and third decades of life, subjecting these patients to a two-
fold or greater lifetime risk of developing colorectal cancer (CRC) than normal subjects.2 A meta-
analysis of colorectal cancer risk suggests a cumulative incidence of malignancy of 2% by 10 
years, 8% by 20 years and 18% by 30 years post diagnosis.1 Sporadic CRC and colitis-associated 
cancer (CAC) together account for 52,000 mortalities every year in the United States alone, 
making them the second leading causes of death from cancer among adults.3 
 
       Unlike sporadic CRC, which develops from an adenomatous polyp, CAC follows a dysplasia-
carcinoma sequence where the inflamed mucosa gives rise to flat and polypoid dysplasia that lead 
to invasive cancers.4, 5 The lack of an elevated growth component, as exists in polyps, creates an 
enormous challenge to detect these flat lesions during surveillance colonoscopy. For example, 50-
80% of the lesions that are missed during surveillance colonoscopy are flat.6, 7 Several murine 
models have been developed to recapitulate human CAC.8 In particular, the azoxymethane-dextran 
sodium sulfate (AOM-DSS) model has been used to demonstrate that advanced cancers develop 
from flat lesions without transitioning through a polypoid intermediate.9 Although dysplasia could 
serve as a marker for malignancy in colitis patients, current surveillance protocols fail to reliably 
identify early stages of CAC.10 
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       Recent advances in biomarker and imaging platforms have focused on either morphological 
or molecular features of these flat lesions, neither of which is sufficient to aid diagnosis of these 
pathologies in-real time during colonoscopy. Efforts to identify polyps and cancerous lesions using 
chromoendoscopy, virtual chromoendoscopy, narrow-band imaging, and post processing 
algorithms such as i-SCAN and FICE have failed to reliably delineate flat lesions from surrounding 
uninvolved tissue.11-14 In particular, chromoendoscopy is currently recommended for routine 
surveillance of IBD patients. Although this technique has improved the detection rates of flat 
lesions from 28% to 56%,15 the fraction of undetected lesions remains unsatisfactory. Similarly, 
optical coherence tomography (OCT) has been used to differentiate diseased from normal 
esophageal tissue, but the inhomogeneous back scattering of signal in high-grade dysplasia limits 
the diagnostic information derived from this approach.16, 17 To improve detection sensitivity, newer 
fluorescence endoscopic techniques such as confocal laser endomicroscopy, have been developed. 
In conjunction with fluorescence contrast agents, these techniques allow visualization of molecular 
signatures of cancer but lack a real-time validation strategy and provide only a limited field of 
view.18-20 
 
The overarching goal for this study is to develop and validate a tri-modal endoscopic system 
consisting of fluorescence, polarization, and color modules for colonoscopy. The color imaging 
module provides conventional visual feedback of the anatomical structures of tissue. Utilizing a 
NIR fluorescent molecular reporter of flat lesions, the fluorescence module highlights underlying 
pathologies that are not visible by conventional color imaging method. Complementary 
polarization signal highlights tissue that is largely opaque to both fluorescence and color modules, 
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thereby facilitating full characterization and instant cross-validation of suspicious lesions. An 
unprecedented high sensitivity and specificity approaching 100% were obtained by combining 
these three imaging modalities. 
2 Materials and Methods 
 
2.1 Using unpolarized light for polarization endoscopy 
Both incident and reflect light are fully described by the Stokes vectors, which contain four 
parameters; S0, S1, S2, and S3. The first Stokes parameter, S0, describes the intensity of the light; 
the second Stokes parameters, S1, describes the difference between horizontal and vertically 
polarized light; the third Stokes parameter, S2, describes the difference between 45 and 135 degree 
polarized light; and the fourth Stokes parameter, S3, describes the difference between left and right 
circularly polarized light. The polarization of light changes upon reflection from a surface, with 
the change based on the reflection geometry and the medium and surface materials. The Mueller 
matrix in Equation 1 mathematically describes the change in polarization for a reflection from a 
tissue,  
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where Θx is difference in the incident and refracted angles ( ), and Θy is the sum of the 
incident and refracted angles ( ).  Snell’s Law (Equation 2) relates the incident and 
refracted angles 
 
 
 
where θi is the incident angle, θr as the refracted angle, and n1 and n2 are the indexes of the media 
and object, respectfully.  Multiplying the incident Stokes vector with the Mueller matrix for 
reflection (Equation 3) results in the Stokes vector for light reflected off of the surface. 
 
 
 
The reflected Stokes vector contains all information needed to compute the Degree of Linear 
Polarization (DoLP) for the reflected light (Equation 4). The DoLP measures how linearly 
polarized the light becomes after reflection, from 0 (no linear polarization) to 1 (completely 
linearly polarized). 
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The Angle of Polarization (AoP) measures the orientation of the reflected light with respect to the 
detector, and is computed from S1 and S2 (Equation 5). 
 
 
 
If the input Stokes vector is unpolarized light [1,0,0,0], the DoLP of the reflected light becomes 
(Equation 6)  
 
 
 
and the reflected AoP is zero, as the reflected S2 component is zero.  This applies only to a planar 
reflection.  On a three dimensional surface, the azimuthal angle is modeled as a rotation of the axis 
of the planar reflection of a microfacet of the surface into the axis of the sensor by a rotation angle 
ϕ.  Using the Mueller matrix of a rotation (Equation 7), 
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the reflection equation becomes (Equation 8) 
 
 
 
The reflected DoLP remains unchanged, however, the AOP becomes equal to the amount of 
curvature (Equation 9).   
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2.2 Synthesis of Polarization filter 
The fabrication of the nanowire polarization filter was conducted at the fabrication 
facilities at Washington University in St. Louis in collaboration with Moxtek Inc. (Orem, UT). 
The nanofabrication of the optical nanowire polarization filter was achieved by first depositing a 
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70 nm thin film of aluminum, followed by a 30 nm thin film deposition of SiO2 using e-beam 
evaporation. A 100 nm thin layer of photoresist S-1805 was spun coated at 3000 rpm and baked at 
115oC for 60 seconds. A continuous-wave single frequency Nd:YAQ laser with 532 nm 
wavelength was used together with a frequency-doubler to produce coherent light waves at 266 
nm wavelength. Two continuous-wave 266 nm wavelengths were aligned to interfere at 110o and 
produce an interference pattern with a period of 140 nm. The interference pattern was transferred 
to the photoresist by exposing the sample for 40 seconds. After developing the photoresist, the 
pattern was transferred to the SiO2 using the standard RIE/ICP etching recipe for SiO2. The SiO2 
was used as a hard mask for etching the aluminum. The aluminum was etched for 150 seconds 
using 30 sccm BCl3, 15 sccm Cl2, 10 mTorr pressure, 70
oC temperature, 100 W RIE power and 
150 W ICP power. The procedure was repeated four times and the sample was rotated by 45o each 
time to produce nanowires with four different orientations. The nanowire polarization filters were 
flip chip bonded to a commercially available CCD imaging sensor (Kodak KAI 2020). 
2.3 Fluorescence and Polarization Endoscope 
The new endoscopic device shown in Fig. 2a is capable of imaging in three different modes: 
RGB, fluorescence, and polarization. In the RGB mode, an endoscopic cold light fountain (Xenon 
Nova 175; Karl Storz, Tuttlingen, Germany) with adjustable light intensity was used as the light 
source. The light cable was coupled to the illumination channel on a 00 Hopkins (1.9 mm x 10 cm) 
straightforward telescope (Karl Storz, Tuttlingen, Germany), as shown in Fig. 2a. Images were 
captured by an NIR-sensitive CCD camera (Fluorvivo; INDEC Biosystems) with an RGB Bayer 
filter. A telescope coupler with a focus ring (Karl Storz, Tuttlingen, Germany) focused the CCD 
camera on the image formation plane at the back of the telescope.  
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In the fluorescence mode, the cold light fountain source was replaced by a 100 mW, 780 
nm excitation source (Lasermax, New York, USA). An 800 nm long-pass emission filter 
(ThorLabs, Newton, New Jersey) was placed behind the telescope in a slit of a custom-made 
adapter designed to couple the macro lens to the telescope. Images were captured using the 
Fluorvivo CCD camera equipped with a Sony ICX285 sensor (quantum efficiency of 30% at 800 
nm).  
In the polarization mode, the same endoscopic cold light fountain used as the light source 
for the RGB imaging was utilized here. Images were captured using the camera housing the 
polarization sensor described earlier.  
2.4 Polarization Endoscopy Calibration  
Since the endoscope is composed of a series of optical elements, the polarization state of 
the input light can be modified as the light travels though the endoscope. Every optical element in 
the endoscope will perturb the Stokes vector of the incident light and these perturbations need to 
be carefully examined to ensure that the endoscope preserves the polarization signatures of the 
incident light.  We created an optical setup to evaluate the polarization properties of the endoscope 
as depicted in Figure 4a. The setup is composed of a polarization state generator and a polarization 
state analyzer. 
 
The polarization state analyzer for the light emerging from the endoscope is measured using a 
division of time polarimeter. The polarimeter is composed of a zero-order precision wave plate 
(Newport 20RP34-514.5) with a quarter wave retardance at 514.5 nm, a precision linear polarizer 
(Newport 20LP-VIS-B) with a wavelength range of 400 – 700 nm and a USB controlled optical 
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power meter (Thorlabs PM100D) with visible spectrum calibrated photodiode (Thorlabs S120V). 
This instrument quantifies the Stokes vector as described by equations (1) through (4):23  
𝑆0 =
1
2
(𝐼(0°, 0°) + 𝐼(45°, 0°) + 𝐼(90°, 0°) + 𝐼(135°, 0°))     (1) 
𝑆1 = 𝐼(0°, 0°) − 𝐼(90°, 0°)    (2) 
𝑆2 = 𝐼(45°, 0°) − 𝐼(135°, 0°)    (3) 
𝑆0 = 𝑆0 − 2𝐼(45°, 90°)    (4) 
 
In these equations, 𝐼(𝜃, 𝜙) is the intensity of the optical beam, 𝜃 describes the linear polarizer 
transmission axis angle in degrees and 𝜙 describes the wave plate retardance, which is 90º for 
the wave plates. To measure (45°, 90°), the light beam passes through a waveplate with the fast 
axis along the x-axis and then through a linear polarizer with transmission axis rotated at 45º; to 
measure 𝐼(𝜃, 0) the beam passes through a linear polarizer with its transmission axis rotated 𝜃 
degrees and then through waveplate with its fast axis along the x-axis. Hence, all measurements 
are done with both linear polarization filter and a quarter wave plate to take into account any 
optical losses that can occur in either optical element. 
2.5 Formulation of LS301 
The near-infrared dye LS301, which was reported previously,21 was synthesized in our lab 
via modification of a previously described method.24 LS301 consists of a near-infrared fluorescent 
dye, cypate (780 ex/ 830 em), and a cyclic peptide sequence, D-Cys-Gly-Arg-Asp-Ser-Pro-Cys-Lys 
(c(DCGRDSPC)K). Fig. 3a shows the molecular structure, absorption, and emission spectra of 
LS301.  
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To formulate LS301 in sol-gel mixture for topical administration, Pluronic F-127 (1 g; 
Sigma Aldrich, St. Louis, MO) was dissolved in phosphate buffered saline (10 mL; PBS) to obtain 
a 10% (w/v) stock solution. A solution of LS301 (0.5 mL; 60 µM) was dissolved in 10% w/v 
aqueous Pluronic solution to form the sol-gel system, which was stored on ice prior to 
administration to maintain its liquid state. 
2.6 In vivo Small Animal Endoscopy 
Mice were anesthetized via intraperitoneal injection of a solution of ketamine (85 mg/kg) 
and xylazine (15 mg/kg). They were then placed supine on a z-translation stage prior to the 
procedure. To avoid unnecessary movements of the endoscope during mode switches and to assess 
a region of interest within the same field of view, the imaging setup was immobilized on a tripod. 
To obtain 1 mm translation inside the colon, the endoscope was set on an x-y translation stage.  
The rigid endoscope could reach as far as 4 cm into the mouse colon, at which point it encountered 
the splenic flexure.  
Prior to topical administration of the LS301 solution, the mouse colon was rinsed with PBS 
to remove debris and mucous. A novel administration technique enabled interaction of the mouse 
tissue with our molecular agent for a longer incubation time than would otherwise be achievable. 
A cold solution of the LS301 in Pluronic F127 sol-gel (0.5 mL) was injected carefully via the 
examination sheath of the endoscope. The solution turned into a gel instantaneously along the 
distal colon. After 10 minutes of incubation, cold PBS was flushed through the examination sheath 
to reverse the gel into a liquid state. After thorough rinsing of the colon with 3-5 PBS washes, 
fluorescence and polarization endoscopy were performed. Steps involved in this process are 
illustrated in Fig. 2b. 
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2.7 In situ fluorescence-polarization imaging 
Post endoscopy, mice were sacrificed and the distal colon was isolated from the peritoneum 
without dislodging it from the animal to locate tumors that were identified during fluorescence-
polarization endoscopy. A 780 nm excitation source illuminated the sample for fluorescence 
imaging and an 800 nm long pass filter was placed in front of the image capture device. Images 
were captured with an exposure time of 0.5 seconds. Polarization imaging was obtained using the 
system described above. 
3 Results 
3.1  Simulating unpolarized light in reflectance polarization endoscopy 
3.1.1 Simulating reflectance imaging using unpolarized light source for polarization endoscopy 
 
Most polarization methods typically use a polarization filter to illuminate a tissue and an 
orthogonal polarization filter placed at the detector side to measure polarization contrast 
information. This imaging modality requires careful optical alignment of the polarization filters 
and is applicable for microscopy or ex-vivo imaging. Due to space constraints in an endoscope, 
polarization contrast imaging is challenging. In this study, we allowed the intrinsic properties of 
tissue to linearly polarize the incident unpolarized light and back scattering to depolarize the 
reflected light, which is captured by our polarization sensor as shown in Fig. 1a. To ensure that 
this polarization technique is sensitive to differences in tissue properties, simulations using Muller 
calculus for reflection and Monte Carlo simulations for back scattering were performed (see 
below) using tissue refractive index values previously reported in literature. Diseased tissues have 
lower refractive index (1.39) than healthy tissue (1.46), thereby serving as an imaging biomarker 
for polarization imaging platform. Given the importance of angle of incidence, DoLP signature 
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arising from healthy and diseased tissues was plotted against the incidence angle using both 
Frenel’s reflectance and Monte Carlo simulations as shown in Fig. 1b and an imaging angle of 15o 
for in vivo endoscopy. At 150, we obtained ~4% DoLP difference between healthy and diseased 
tissue, which is sufficient to delineate normal from diseased tissue. While standard endoscopy 
procedures range in angles of imaging between 15-350, our ex vivo imaging setup utilized a 350 
angle, which results in a DoLP change of 20% between healthy and diseased tissue according to 
Fig. 1b. Based on differences in tissue refractive indexes, radius and density of nuclei, absorption 
coefficient between healthy and diseased tissue25, 26 and back scattering of light, we illustrate the 
propagation of light in the two stages of CAC development: adenomatous polyp and flat, depressed 
lesions, respectively This simulation demonstrates that the polarization method is capable of cross-
validating CAC and associated flat lesions in real time, guided by enhanced fluorescence in 
pathologic tissue. 
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Fig. 1. Concept of reflectance imaging using unpolarized light. (a)Case 1 illustrates the propagation of light in healthy 
mucosa. Unpolarized light illuminates the region of colon under investigation. Light returning back from the wall of 
the colon interacts with the healthy mucosa as shown, and gets partially polarized prior to detection in a tissue 
composition dependent manner. Cytoskeletal organized actin fibers partially polarize the light.  Case 2 illustrates the 
propagation of light in a flat, depressed lesion. Unpolarized light reflected from the wall of the colon interacts with 
pathologic tissue, which depolarizes the light. Larger and denser nuclei serve as source of scatterers in cancer cells, 
which favors depolarization. (b) A plot of Degree of Linear Polarized (DoLP) light versus incident angle of 00 
straightforward endoscope. Reflected light from tumor tissue (blue) and healthy tissue (red) is modeled using both 
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Frenel’s reflectance and Monte Carlo simulations. Dotted vertical black lines serve as a comparative tool for DoLP 
signature at 150 (in vivo studies) and 350 (ex vivo studies). 
 
3.1.2 Simulating unpolarized light for polarization endoscopy 
To ensure that this polarization technique is sensitive to differences in tissue properties, 
simulations using Muller calculus for reflection and Monte Carlo simulations for back scattering 
were performed. The difference in polarization signatures is due to a combination of Fresnel 
reflectance and backscattered intensity from the unpolarized source.  The incident, unpolarized 
light becomes partially polarized upon reflection as shown in Fig. 1a.  The partially polarized light 
mixes with the backscattered intensity from the tissue and further depolarizes the incident light, 
due to the optical parameters of the tissue.  Assuming that scattering comes mostly from the 
nucleus, backscatter is simulated as a dispersion of spheres with optical properties similar to those 
of the nucleus, performed using the algorithm reported previously.27 In tumor tissue, scattering 
comes mostly from the large sized, dense nuclei, whereas in uninvolved tissue, scattering arises 
primarily from scatterers associated with the mucosa and submucosa regions.  Verification is done 
using polarized Monte Carlo simulation software with a poly-disperse set of scatterers drawn from 
a uniform distribution. In order to simulate the differential optical parameters arising from tumor 
versus unhealthy tissue, differences in nuclear radii, density of nuclei, index of refraction of nuclei, 
and absorption coefficient were considered and obtained from literature.28-31 Perelman et al. have 
successfully extracted valuable information about the density and size distribution of mucosal cells 
and used them as indicators of disease state (neoplastic precancerous changes in biological tissue). 
Increase in size and density of nucleus is associated with a later diseased state in these studies. 
Furthermore, this is supported by Backman, et al. Studies conducted illustrate the higher level of 
backscattered light associated with a denser and larger nuclei concentration. This leads the 
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polarization state of reflected light to be more depolarized when compared to healthy tissue 
comprising of uniformly distributed, less dense, smaller nuclei.  
We took a similar approach in modeling backscattered intensity as the combination of backscatter 
from the mucosa added to the backscatter from the submucosa after propagation back through the 
mucosa.26  Since the light used was a 6000K Xenon source, the simulations take place at 
wavelengths between 400nm and 700nm in 25nm increments, normalized to the intensity of the 
bulb at these wavelengths. Increase in backscatter from the tumor tissue effectively depolarizes 
the Fresnel reflected DoLP, resulting in a lower measured DoLP for tumor when compared to the 
surrounding uninvolved region. 
 
3.2  Development of trimodal color, fluorescence, and polarization endoscope 
 
The goal of the instrument development was to retain the features of widely used clinical 
endoscopes while incorporating new reporting strategies for enhanced diagnosis of endoscope-
accessible organs. Toward this goal, we developed a novel endoscope that is capable of presenting 
imaging data in color (RGB), NIR fluorescence, and polarization modes. Color colonoscopy is the 
standard of care, while NIR fluorescence and polarization provide new reporting signals for a 
molecularly targeted imaging agent and tissue pathophysiology, respectively. A detailed 
description of the endoscopy procedure is available in Methods (In vivo small animal endoscopy). 
Briefly, a rigid Hopkins endoscope fitted with a xenon lamp and a 780 nm laser served as 
RGB/polarization and NIR light sources, respectively, as shown in Fig. 2a and Fig. 2b. We used a 
visible/NIR-sensitive CCD camera with an RGB Bayer filter and 25% quantum efficiency at 800 
nm to capture both color and NIR images.   
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Fig. 2: Trimodal color-fluorescence- polarization endoscopy utilizing a novel molecular probe administration 
approach. (a) Endoscope setup used to perform white light, fluorescence and polarization endoscopy. A telescope 
coupler with a focus ring was used to focus the image onto the image formation plane located at the back of the Karl 
Storz telescope lens. For white light endoscopy, Xenon Nova 175 was used as a light source and a CCD camera 
(Fluorvivo) with an RGB Bayer filter was used. In NIR- fluorescence mode, a 100 mW 780 nm laser excitation source 
(inset I) was coupled to the light source channel on the endoscope. An 800 nm long pass emission filter was placed 
behind the telescope, as shown in the figure. A CCD camera with NIR capabilities (Fluorvivo) was utilized to capture 
images in NIR-fluorescence mode. In polarization mode, the Xenon broadband light source was used along with a 
custom made polarization camera, as shown in inset II. The entire setup was fixed on a tripod and an X-Y translation 
stage was utilized for finer adjustments to avoid causing damage to the walls of the colon.  (b) Steps involved in the 
dye administration method utilizing Pluronic F127 gel formulation. (c) Schematic of the light path associated with the 
endoscopy setup presented in (A). (d) Polarization sensor consisting of an imaging array arranged in blocks of four 
(two-by-two) superpixels. Each superpixel consists of four pixels that are composed of nano-wire polarization filters 
with the transmission axis oriented at 00, 450, 900, and 1350. These nanowires are 70 nm wide, 140 nm tall, and spaced 
140 nm from center to center. 
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3.2.1 Real time polarization imaging  
 
To capture the light polarization information, a division of the focal plane polarization 
imaging sensor was developed, where the incoming light was filtered via a polarization filter array 
consisting of four nanowire polarization filters offset by 450 prior to absorption by a silicon 
photodiode as shown in Fig. 2d.32, 33 The amplitude of the filtered light wave was recorded by 
photodetectors underneath the aluminum nanowire polarization filters. The tissue was illuminated 
with unpolarized light via the light port of a Karl Storz rigid endoscope and the reflected light was 
collected via our custom-built polarization sensor. The polarization state of the reflected light from 
the tissue was determined by both the relative position of the camera and the index of refraction 
of the imaged tissue, (Equation 4). The use of an unpolarized light source simplified the imaging 
setup and allowed the intrinsic morphological and physiological properties of the tissue to dictate 
the captured polarization signature. This imaging method differs from typical polarization contrast 
imaging, where linear polarized illumination is used to illuminate a tissue and a detector with cross 
linear polarization is used to record the reflected light. Due to complex alignment requirements of 
the polarization filters on both the illumination and detection components, application of 
traditional polarization contrast imaging is limited for in vivo endoscopy. 
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Fig. 4 Optical setup and characterizations involved for evaluating the performance of the endoscope. (a) A polarization 
state generator is used to illuminate the endoscope and a polarization state analyzer is used to evaluate the polarization 
performance of the endoscope. (b) Measurements of the polarization performance of the endoscope. The endoscope 
is illuminated with linearly polarized light between 0 and 180 degrees. While the DoLP decreases by ~20% due to 
retarder elements in the endoscope, DOP remains at 100%, indicating involvement of circular polarization component. 
(c) Measured angle of polarization for the light emerging from the endoscope. The endoscope is illuminated with 
linearly polarized light between 0 and 180 degrees. The endoscope does not affect the angle of polarization of the 
incident light. 
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3.2.2 Polarization performance of the endoscope: calibration study 
 
 In order to examine how the polarization state of the input light is modified as the light 
travels through the endoscope, we created an optical setup as shown in Fig. 4a. The polarization 
properties of light emerging from the endoscope when illuminated with linearly polarized light 
between 0 and 180 degrees are presented in Fig. 4b, 4c.  
 Figure 4b presents the measured degree of linear polarization, degree of circular 
polarization and degree of polarization of the light exiting the endoscope. As light is transmitted 
through the endoscope, the degree of linear polarization drops to around 80% and the circular 
polarization equally increases. Hence the degree of polarization remains around one, which 
indicates that there are very low optical losses, scattering events and sources of depolarization in 
the endoscope. We believe that the introduction of elliptically polarized light in the endoscope is 
probably due to retarders that are placed inside the probe. Once the retardance of the endoscope is 
known, calibration routines can provide the correct input Stokes vector.34 Furthermore, Fig. 4c 
represents the angle of polarization of the output Stokes vector that is not affected by the optical 
elements of the endoscope.  
 
3.3 Targeting adenomatous tumor and dysplasia in AOM-DSS tissue sections with NIR 
fluorescent dye-labeled octapeptide (LS301) 
Some colon lesions lie below the mucosa, requiring imagining techniques with depths 
beyond a few millimeters. Capitalizing on the ability of NIR light to penetrate deeper into tissue 
with low background autofluorescence compared to visible light, we used a NIR fluorescent dye-
labeled octapeptide, LS301; see a and 3b, which has been shown to selectively accumulate in 
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malignant tumors.21 We explored the feasibility of using LS301 to detect inflammation-driven 
colon carcinogenesis using the clinically relevant AOM-DSS murine model. Precancerous and 
cancerous lesions from AOM-DSS mouse colons were identified and sectioned before incubation 
with LS301, and the slides were imaged by fluorescence microscopy. Fig. 3c demonstrates that 
LS301 uptake was highly specific for adenomatous tumor, with minimal fluorescence from the 
surrounding uninvolved regions. The contrast between adenomatous tumor and surrounding 
uninvolved tissue was 56 ± 9 (standard error of the mean, s.e.m. was used in this study) with an 
average contrast-to-noise-ratio (CNR) of 7 ± 1.13. This impressive level of specificity of LS301 
was maintained when evaluating tissues exhibiting features sensitive to pre-cancerous lesions, 
such as aberrant crypt foci as illustrated in Fig. 3d. For example, the contrast between dysplastic 
lesions and the surrounding uninvolved region as shown in Fig. 3e was 37.4 ± 3.6 with an average 
CNR of 8.72 ± 0.88. In contrast, the dye cypate alone did not show any selective uptake in the 
colon lesions.  Therefore, we used LS301 for subsequent in vivo studies of the AOM-DSS model.  
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Fig. 3 Ex-vivo fluorescence imaging using LS301 on AOM-DSS tissue sections. (a) Molecular structure of LS301. (b) 
Absorption and emission spectra of LS301. (c) H&E and corresponding NIR fluorescence stains of tumors identified 
along the distal colon of a mouse treated with AOM-DSS. Arrow points the regions of the tumor that exhibit enhanced 
binding of LS301. Black and red dotted lines identify the region that marks the initiation of adenomatous tumor. (d) 
H&E and corresponding NIR fluorescence stains of dysplastic lesions identified along the colon of mice treated with 
AOM-DSS. Regions marked by red dotted lines mark the boundaries of the crypts. Arrows point to regions along the 
aberrant crypts towards which LS301 demonstrates preferential binding. (e) H&E and corresponding NIR fluorescence 
stains of normal ascending colon of mice treated with AOM-DSS displaying minimal non-specific probe binding 
towards muscularis mucosa.  
 
3.4 In vivo fluorescence and polarization endoscopy 
3.4.1 NIR fluorescence endoscopy utilizing novel topical administration method in AOM-DSS 
and wound-healing models 
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Having demonstrated the feasibility of detecting CAC and dysplasia by fluorescence 
imaging and established the polarization contrast between diseased and normal tissues, we next 
assessed the use of these combined techniques for in vivo imaging. Previous small animal imaging 
of tumors with LS301 have relied on the intravenous administration of the molecular probe.21 
Typically, a wait time of 24 hours is needed to obtain excellent contrast between tumors and 
uninvolved surrounding tissue. While this imaging time point is acceptable for many clinical 
applications, a fast-acting approach would be preferred for colonoscopy. Toward this goal, we 
explored a topical delivery method in which the molecular probe is sprayed on the colon during 
screening endoscopy. We found that poloxamer (Pluronic F127), which is approved for human 
use, can solubilize LS301 (see Fig.2B; Methods, Formulation of LS301). More importantly, the 
formulation undergoes reversible thermoresponsive sol-gel transition, with a critical transition 
temperature of 20oC. This previously unexplored topical application of NIR molecular probes 
allowed endoscope-mediated spraying of the cold formulation, resulting in a rapidly formed thin 
layer of gel around the colon tissue. With this method, we observed a mean CNR of 20.64 ± 1.65 
between the adenomatous tumor and surrounding uninvolved tissue, and 12.1± 1.03 between flat 
lesions and surrounding uninvolved regions as displayed in Fig. 5a and 6a respectively. These 
outcomes represent a six-fold and three-fold increase in mean fluorescence intensity from the 
adenomatous tumor and flat lesions, respectively, relative to surrounding uninvolved tissues.  
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Fig. 5 In vivo and in situ fluorescence and polarization endoscopy of adenomatous tumor-surrounding un-involved 
boundary. (a) In vivo fluorescence and polarization endoscopy. (i) RGB color image of the tumor identified in the 
distal colon of an AOM-DSS treated mouse. (ii) Fluorescence image clearly identifies boundaries of the tumor. (iii) 
Grayscale image consisting of DoLP and AOP information in the polarization mode at 30 frames per second. Bright 
spot in image is from the light source. (iv) Thresholded DoLP mask image identifies inflamed regions (reported as 
DoLP value above 10%; red color) and cancerous regions (DoLP value under 5%; green color). (b) Ex-vivo (i) RGB, 
(ii) NIR fluorescence, and (iii) polarization images of tumor identified in (a). Dotted yellow lines in (i) and (ii) indicate 
the boundary of the tumor. Thresholded DoLP mask image identifies cancerous regions (DoLP value under 10%; 
green color) (c) Histological validation of adenomatous tumor identified in (b), along with corresponding NIR 
fluorescence intensity. Dotted rectangle identifies the region under investigation in (ii and iv). Arrow indicates the 
direction of molecular probe administration. UT: Uninvolved Tissue, PP: Peyer’s patch, AT: Adenomatous Tumor 
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Fig. 6 In vivo and ex vivo fluorescence and polarization endoscopy of flat lesion-surrounding un-involved 
boundary. (a) In vivo fluorescence and polarization endoscopy. (i) RGB color image of the flat lesion 
identified in the distal colon of an AOM-DSS treated mouse. Dotted green line outlines the boundary of the 
Peyer’s patch. Dotted blue line outlines the boundary of the flat lesion biopsied in accordance to 
corresponding fluorescence image. Dotted black circle identifies the region that was investigated more 
closely (iii) and serves as the field of view region for the remaining in vivo images. Grayscale image 
consisting of DoLP and AOP information in the polarization mode at 30 frames per second. (v) 
Corresponding region to (iii) identified by polarization camera in grayscale (vi) Thresholded DoLP mask 
image identifies Peyer’s patch (reported as DoLP value above 10%; red color) and flat lesion (reported as 
DoLP value less than 5%; green color). (b) Ex-vivo RGB (i), NIR fluorescence (ii), and DOLP (iii) images 
of flat lesion identified in (a). Dotted blue line indicates the boundary of the flat lesion (FL) and dysplastic 
tissue (d). (ii) Corresponding NIR fluorescence image demonstrates fluorescence signal from flat lesions 
and dysplastic tissue. (iii) Dotted red lines indicate the corresponding flat lesion and dysplastic tissue. 
Thresholded DoLP mask image identifies cancerous regions (DoLP value under 10%; green color) (c) 
Histological validation of flat lesion, dysplastic tissue and Peyer’s patch identified in (a) and (b) along with 
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corresponding NIR fluorescence intensity, respectively. For the flat lesion, black solid arrows indicate the 
boundary of tumor in the H&E and NIR fluorescence images. For dysplastic tissue, black solid arrows 
indicate the aberrant crypts identified by LS301 in the H&E image and white solid arrows in the NIR 
fluorescence image. A dotted red line indicates the boundary of the Peyer’s patch in the H&E and NIR 
fluorescence image. PP: Peyer’s patch, FL: Flat Lesion 
 
 
Fig. 7 In vivo and ex vivo fluorescence and polarization endoscopy of wound healing inflammation model.   (a) Ex 
vivo brightfield images of wounds created via endoscopy procedure in vivo. (i,ii) Wound bed at day 4 post endoscopic 
injury. Dotted red line marks the neutrophil cap formed as a result of inflammation. (iii) RGB color image of the 
corresponding wound bed identified in (i) within the distal colon of an injury mouse. (iv) Corresponding NIR 
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fluorescence image demonstrates very minimal binding of the probe towards the proliferative cells in the neutrophil 
cap. (v) Grayscale image captured using the polarization camera. Dotted red line marks the neutrophil cap region. (vi) 
Corresponding thresholded DoLP mask image identifying regions higher than established value of 10.6%. (b) Ex vivo 
brightfield images of wounds created via endoscopy procedure in vivo. (i,ii) Wound bed at day 4 post endoscopic 
injury. Dotted red line marks the boundary of the wound bed. (iii) RGB color image of the corresponding wound bed 
identified in (i) within the distal colon of an injury mouse. (iv) Corresponding NIR Fluorescence image demonstrates 
minimal binding of the probe towards the wound bed (v) Grayscale image captured using the polarization camera. 
Dotted red line marks the boundary of the wound bed. (vi) Corresponding, thresholded DoLP mask image identifying 
regions higher than established value of 10.6%. (c) Ex vivo fluorescence binding pattern and histologic validation. 
(i,ii,iii) H&E images of disrupted epithelium in the inflamed wound region identified in (a). (iv,v,vi) Corresponding 
NIR fluorescence microscopy images identify proliferative cells in the wound bed. (d) Ex vivo fluorescence binding 
pattern and histology validation. (i,ii,iii) H&E images of wound bed in (a). (iv,v,vi) Corresponding NIR fluorescence 
microscopy images identify proliferative cells in the wound bed. 
 
Inflamed tissues generally retain optical contrast agents by several mechanisms, including 
non-specific retention or entrapment by activated macrophages. Peyer’s patches are sites of the 
host defense system where macrophages, dendritic cells, B-lymphocytes, and T-lymphocytes 
reside.  We observed that LS301 did not accumulate in Peyer’s patches in the mucosa as shown 
by Fig. 6c. The lack of LS301 fluorescence in this tissue indicates the high selectivity of the 
imaging agent for cancer-associated lesions. To further assess the feasibility of distinguishing 
wound-repair associated inflammation from colon cancer and dysplasia, we induced colon injury 
in mice by removing single full thickness areas of the mucosa and submucosa using a flexible 
biopsy needle. The leading edge of injured epithelium is known to form cables of actin filaments 
extending from cell-to-cell, forming a ring around the wound circumference and facilitating wound 
closure.35 Topical administration of LS301 resulted in a barely detectable mean CNR of 1.62±0.41 
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between inflamed regions and surrounding uninvolved regions in this wound-healing model using 
our current fluorescence endoscope as shown in Figure 7. Ex-vivo sections of exteriorized colon 
from the tumor and inflamed regions were examined as shown in Fig. 5b and 6b. Consistent with 
in-vivo results, identified adenomatous tumor and flat lesions showed high fluorescence intensity 
as seen in Fig. 5c and 6c. A graded fluorescence intensity pattern was observed within the 
adenomatous tumor mass as shown in 5c, illustrating the diffusion and retention of LS301 in the 
lesions within ten minutes of administration. LS301 also showed high specificity towards 
dysplastic lesions possessing features such as aberrant crypt foci as shown in Fig. 6c. Fig. 7a 
demonstrates minimal fluorescence in the lumen of colonic crypts and features of inflammation, 
such as regions of neutrophil activation. H&E staining confirmed the presence of these 
morphological features as shown in Fig. 7c and 7d. Ex-vivo studies demonstrated relatively higher 
fluorescence intensities from regions exhibiting higher epithelial proliferation, which is a 
consequence of wound-repair as shown in Fig. 7c.  
3.4.2 Polarization endoscopy utilizing DoLP contrast in AOM-DSS and wound healing 
inflammation models 
The fluorescence molecular imaging approach deployed above does possess certain 
limitations.  It does not furnish structural information that is useful for validating the presence of 
cancer or dysplasia, so this information much be obtained via ex vivo histologic validation. Ex vivo 
histology requires tissue biopsy and offline analysis that could delay clinical decisions and result 
in repeat hospital visits. Although the molecular fluorescence method can distinguish inflamed 
from cancerous tissue or flat lesions, a complementary method that can instantly validate the 
negative fluorescence contrast in suspicious but non-cancerous tissues would facilitate rapid 
clinical decision making during colonoscopy. Finally, the topical application of fluorescence 
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molecular probes and the subsequent washing step occasionally leave residual dye and gel in the 
vicinity of uninvolved tissue, which could be misinterpreted as cancerous. To resist oversampling 
of the colon through purely fluorescence guided biopsies and provide real-time confirmation of 
suspicious lesions, we incorporated the DoLP contrast obtained from reflectance polarization 
imaging into our fluorescence endoscope. Both the fluorescence and DoLP contrasts are 
orthogonal, providing complementary positive fluorescence and DoLP signals in cancerous and 
uninvolved colon tissues, respectively, but negative fluorescence and DoLP signals in uninvolved 
and cancerous colon tissues, respectively. To rule out false positive DoLP signature caused by the 
irregular contours of the colon, a small field of view was used to interrogate tissue highlighted by 
molecular fluorescence imaging.    
Post-acquisition, regions of interest were selected to quantify the DoLP signature as shown 
in video 1. For adenomatous polyps, a mean DoLP value of 0.0414 ± 0.0142 was obtained 
compared to 0.0816 ± 0.0173 from the surrounding uninvolved regions. We found a similar trend 
for flat lesions, with a mean DoLP of 0.0225 ±0.0073 compared to 0.0924 ± 0.0284 from the 
surrounding wall as shown in video 2. While the fluorescence imaging was able to detect 
pathologic tissue, the high DoLP signal in uninvolved tissue provides an anatomical landscape of 
the colon and identifies different types of uninvolved colon tissue. For example, Peyer’s patches, 
which were not detected by fluorescence, had a high mean DoLP signal of 0.1064 ± 0.0104, 
compared to 0.0872 ± 0.022 from surrounding wall (video 1). These differences in DoLP signal 
are probably due to the higher structural integrity of Peyer’s patches caused by the high density of 
lymphoid tissue. In the wound-healing model, the increase in newly formed actin filaments 
resulted in a high birefringence signal, thereby polarizing the incident light in the process.36  For 
example, a high mean DoLP signal of 0.1363 ± 0.0379 was obtained along the epithelium 
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surrounding the wound bed as demonstrated in Fig. 7a and 7b.  Thus, the combined high 
polarization and low LS301 fluorescence signals in non-tumor tissue provide real-time validation 
of suspicious lesions during endoscopy, which reduces the number of false-positives and 
unnecessary biopsies.  
To examine colon tissue under controlled conditions and provide maximum contrast, ex-
vivo polarization imaging was conducted at 350 using the tissue from the in vivo study. Consistent 
with the in vivo studies, Fig. 6b exhibits a lower DoLP signature was obtained for flat lesions 
compared to surrounding uninvolved regions. Patches of higher DoLP signature were observed 
around the flat lesion, clearly identifying the non-tumor Peyer’s patch. 
 
4 Discussion 
We have developed an integrated fluorescence and polarization endoscope for detecting 
and providing real-time confirmation of CAC, dysplasia, and associated flat lesions that are 
difficult to detect without ex vivo histologic validation. Although depressed cancerous lesions and 
sessile serrated adenomas have different pathology, we used the term flat lesions for both flat 
depressed carcinomas and adenomas to reflect the similarity in the level of difficulty in detecting 
these lesions during conventional colonoscopy. Unlike current endoscopic techniques that 
interrogate molecular or structural signatures of CAC and dysplasia, the combined fluorescence 
and polarization contrasts create a new paradigm for identifying colonic lesions with high 
accuracy. The murine AOM-DSS model used in this study recapitulates the molecular pathways 
and morphological features of CAC from dysplasia to carcinoma.37 Similarly, the murine wound-
healing model exhibits key features of inflammation that are reminiscent of malignancy. These 
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include wound-associated epithelial cell proliferation and stromal neutrophil and macrophage 
recruitment in the wound bed.   
Our fluorescence imaging approach is similar to chromoendoscopy, where non-tumor 
targeted dyes are applied topically for improved visualization of dysplastic lesions.11, 38 Previous 
studies attempted to use the FDA-approved NIR dye, indocyanine green (ICG), to enhance the 
detection of submucosal colon lesions and minimize tissue autofluorescence.39 Unfortunately, the 
high background ICG fluorescence in the subserosa around the tumor confounded data analysis. 
In a recent study, we showed that LS301 selectively accumulates in tumors and achieves high 
tumor-to-background fluorescence at 24 hour post intravenous injection.21 Using the AOM-DSS 
treated mouse model of CAC, we demonstrated in this study that ex-vivo staining of colon tissue 
with LS301 successfully identified adenomatous tumors and dysplastic lesions in the colon tissue 
as shown in Fig. 3c and 3d. Ex vivo histologic validation confirmed the in vivo imaging analysis. 
These results demonstrate that molecular fluorescence endoscopy, aided by LS301, detects 
multiple stages of oncogenesis with high potential to improve the management of colorectal 
cancer. 
However, the intravenous administration of LS301 and the long wait time (24 h) to achieve 
high fluorescence contrast between tumors and uninvolved surrounding colon tissue are not 
suitable for colonoscopy. In addition, the excretion of LS301 through the hepatobiliary pathway 
after intravenous injection increases background NIR fluorescence in the colon, compounding the 
detection of flat lesions and dysplasia. Based on our ex vivo study, we postulated that the rapid and 
prolonged retention of LS301 in pathologic tissues lends it to topical administration during 
colonoscopy. The results demonstrate that the formulation of LS301 in a poloxamer sol-gel 
transition system allowed us to topically administer the imaging agent with a spray catheter during 
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endoscopy. In contrast to the use of generic dyes for chromoendoscopy, the selective uptake of 
LS301 in CAC and dysplastic colon tissue minimized nonspecific uptake in uninvolved mucosa, 
ushering in a new procedure for topical administration of tumor-targeted molecular probes. The 
commercially available poloxamer not only improved the solubility of the hydrophobic LS301, 
but also aided in the uniform coating of the tissue, thereby increasing the interaction of the 
molecular probe gel formulation with the colon tissue under investigation. The observed high mean 
CNR obtained from adenomatous tumors and flat lesions compared to surrounding uninvolved 
tissue is a function of the improved molecular probe selectivity for tumors, reduced 
autofluorescence in the NIR imaging window, and enhanced incubation time provided by the sol-
gel formulation. This sol-gel approach can be extended to previously reported methods for imaging 
colon cancer and dysplasia. These include Cy5.5 labeled cathepsin B substrate used to identify 
polyps in adenomatous polyposis coli (Apc min) mice40 and fluorescein-labeled VRPMPLQ 
heptapeptide that was shown to preferentially bind dysplastic rather than normal mucosa.19 Unlike 
these molecular probes which are confined to identifying only specific stages of tumorigenesis,41, 
42 LS301 uniquely captures multiple stages of cancer development. A limitation of the sol-gel 
method is the lag time between topical application and imaging. Our current protocol uses about 
10 minutes to optimize tumor uptake. A future goal is to optimize the procedure to shorten the 
incubation time for rapid assessment of the colon.  
Although the topical administration of LS301 has enormous benefits for screening 
endoscopy, we found that polarization contrast can provide real-time cross-validation of suspicious 
lesions with an orthogonal but complementary signal. This approach is expected to minimize the 
need for ex vivo biopsy, accelerate medical decisions, and improve clinical outcomes with minimal 
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recall rates. In addition, false positive fluorescence arising from residual gelatinous materials in 
healthy colon can readily be identified by the low polarization contrast in healthy tissue.  
Previous studies have reported the use of polarized light scattering spectroscopy and 
reflectance spectroscopy for tissue analysis.28, 43, 44 In these studies, ex vivo colonic tissue 
specimens were illuminated with polarized light and morphological maps of the specimens were 
constructed based on varying nuclear sizes, population density and refractive index.28, 43, 44 
However, the system configuration and challenges in real-time mapping of the polarization signal 
undermine its use for in vivo applications. We circumvented these challenges by developing an 
imaging configuration and sensor setup capable of reporting DoLP and AOP changes in the 
reflected light, while taking into account the relative positions of the camera with respect to the 
tissue. As DoLP reports on the fraction of reflected light that is linearly polarized, we expect 
differences between the DoLP signature in epithelial layer of diseased and healthy tissue. Pre-
cancerous and cancerous lesions within the epithelial layer possess distinct morphological features, 
such as increased nuclear size and increased nuclear-cytoplasmic ratio, which results in significant 
multiply scattered components of light and a corresponding decrease in DoLP signature. A mean 
DoLP change of 4% was obtained for polypoid tissue in the surrounding uninvolved region. This 
change was validated by simulation results as depicted in Fig. 1b, where we predicted a change of 
4% in DoLP signature when imaging at 150.  In the case of flat lesions, we obtained a DoLP 
difference of 7% relative to the surrounding Peyer’s patch regions. The exceptionally high DoLP 
signal in Peyer’s patches stems from the formation of firmly matted fibrotic bands within the serosa 
and mesentery as shown in video 1. The increase in concentration of linearly birefringent material, 
such as actin, results in a DoLP difference of 10% in the inflamed regions compared to surrounding 
uninvolved colonic tissue. We demonstrated our ability to rapidly interrogate regions of interest in 
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real time (at 40 frames per second) without distortion from motion artifacts arising from respiration 
and peristalsis as shown in videos 1 and 2.   
In summary, the combination of a tumor-targeting molecular probe, topical application of 
a contrast agent with a biocompatible sol-gel formulation, and the development of a multimodal 
color, NIR fluorescence, and polarization endoscope provides a new paradigm for the accurate 
detection of colonic lesions, including CAC, dysplasia, and the associated flat lesions. Extension 
of this approach to a wound-healing inflammation model22 demonstrated a reversal of the 
fluorescence-polarization signal, highlighting the complementary nature of both techniques. The 
ease of incorporating both fluorescence and polarization fibers into an existing endoscope allows 
seamless integration into current screening colonoscopy protocols. A similar approach can be 
envisaged for other forms of epithelial cancer such as esophageal, cervical, bladder, skin, and 
stomach tumors that account for over 65% of the non-colorectal cancer deaths. 
 
5    Acknowledgements 
We thank Mr. Nick Manieri for his assistance with the endoscopy and biopsy procedure on the 
AOM-DSS and wound-healing inflammation mice. We also thank Dr. James Ballard for reading 
the manuscript. The authors acknowledge funding support from US National Institutes of Health 
including R01 CA171651 (NCI). TC was supported by NIH grant F31 CA171798. The authors 
of this manuscript have no competing interests. 
 
134 
 
6    References 
1.     J. A. Eaden et al., "The risk of colorectal cancer in ulcerative colitis: a meta-analysis," Gut 
48(4), 526-535 (2001). 
2.     N. A. Molodecky et al., "Increasing incidence and prevalence of the inflammatory bowel 
diseases with time, based on systematic review," Gastroenterology 142(1), 46-54 e42; quiz e30 (2012). 
3.     R. Siegel et al., "Cancer Statistics, 2012," A Cancer Journal for Clinicians 62(1), 10-29 (2012). 
4.     S. D. Markowitz et al., "Molecular origins of cancer: Molecular basis of colorectal cancer," 
The New England journal of medicine 361(25), 2449-2460 (2009). 
5.     S. H. Itzkowitz et al., "Inflammation and cancer IV. Colorectal cancer in inflammatory bowel 
disease: the role of inflammation," American journal of physiology. Gastrointestinal and liver physiology 
287(1), G7-17 (2004). 
6.     R. Kiesslich et al., "Methylene blue-aided chromoendoscopy for the detection of intraepithelial 
neoplasia and colon cancer in ulcerative colitis," Gastroenterology 124(4), 880-888 (2003). 
7.     T. Ullman et al., "Progression of flat low-grade dysplasia to advanced neoplasia in patients 
with ulcerative colitis," Gastroenterology 125(5), 1311-1319 (2003). 
8.     M. Kanneganti et al., "Animal models of colitis-associated carcinogenesis," Journal of 
biomedicine & biotechnology 2011(342637 (2011). 
9.     C. Neufert et al., "An inducible mouse model of colon carcinogenesis for the analysis of 
sporadic and inflammation-driven tumor progression," Nature protocols 2(8), 1998-2004 (2007). 
10.     F. A. Farraye et al., "AGA technical review on the diagnosis and management of colorectal 
neoplasia in inflammatory bowel disease," Gastroenterology 138(2), 746-774, 774 e741-744; quiz e712-
743 (2010). 
11.     M. F. Neurath et al., "Is chromoendoscopy the new standard for cancer surveillance in patients 
with ulcerative colitis?," Nature clinical practice. Gastroenterology & hepatology 6(3), 134-135 (2009). 
12.     A. Hoffman et al., "High definition colonoscopy combined with i-Scan is superior in the 
detection of colorectal neoplasias compared with standard video colonoscopy: a prospective randomized 
controlled trial," Endoscopy 42(10), 827-833 (2010). 
13.     C. Becker et al., "High resolution colonoscopy in live mice," Nature protocols 1(6), 2900-2904 
(2006). 
14.     F. Emura et al., "Narrow-band imaging optical chromocolonoscopy: advantages and 
limitations," World journal of gastroenterology : WJG 14(31), 4867-4872 (2008). 
15.     J. Pohl et al., "Pancolonic chromoendoscopy with indigo carmine versus standard colonoscopy 
for detection of neoplastic lesions: a randomised two-centre trial," Gut 60(4), 485-490 (2011). 
16.     P. A. Testoni et al., "Optical coherence tomography in detection of dysplasia and cancer of the 
gastrointestinal tract and bilio-pancreatic ductal system," World journal of gastroenterology : WJG 
14(42), 6444-6452 (2008). 
17.     E. Zagaynova et al., "Endoscopic OCT with forward-looking probe: clinical studies in urology 
and gastroenterology," Journal of biophotonics 1(2), 114-128 (2008). 
18.     S. Foersch et al., "Molecular imaging of VEGF in gastrointestinal cancer in vivo using 
confocal laser endomicroscopy," Gut 59(8), 1046-1055 (2010). 
19.     P. L. Hsiung et al., "Detection of colonic dysplasia in vivo using a targeted heptapeptide and 
confocal microendoscopy," Nature medicine 14(4), 454-458 (2008). 
20.     H. Neumann et al., "Confocal laser endomicroscopy: technical advances and clinical 
applications," Gastroenterology 139(2), 388-392, 392 e381-382 (2010). 
21.     Y. Liu et al., "Hands-free, wireless goggles for near-infrared fluorescence and real-time image-
guided surgery," Surgery 149(5), 689-698 (2011). 
22.     H. Seno et al., "Efficient colonic mucosal wound repair requires Trem2 signaling," 
Proceedings of the National Academy of Sciences of the United States of America 106(1), 256-261 
(2009). 
135 
 
23.     T. York et al., "Characterization of a visible spectrum division-of-focal-plane polarimeter," 
Applied optics 51(22), 5392-5400 (2012). 
24.     S. Achilefu, et al., "Synthesis, in vitro receptor binding, and in vivo evaluation of fluorescein 
and carbocyanine peptide-based optical contrast agents," Journal of medicinal chemistry 45(10), 2003-
2015 (2002). 
25.     T. V, Tissue Optics: Light Scattering Methods and Instruments for Medical Diagnosis, SPIE, 
Bellingham, WA (2000). 
26.     D. Hidovic-Rowe et al., "Modelling and validation of spectral reflectance for the colon," 
Physics in medicine and biology 50(6), 1071-1093 (2005). 
27.     J. Ramella-Roman, et al., "Three Monte Carlo programs of polarized light transport into 
scattering media: part I," Optics express 13(12), 4420-4438 (2005). 
28.     V. Backman et al., "Detection of preinvasive cancer cells," Nature 406(6791), 35-36 (2000). 
29.     R. S. Gurjar et al., "Imaging human epithelial properties with polarized light-scattering 
spectroscopy," Nature medicine 7(11), 1245-1248 (2001). 
30.     L. T. Perelman, "Observation of Periodic Fine Structure in Reflectance from Biological Tissue: 
A New Technique for Measuring Nuclear Size Distribution," Phys. Rev. Lett. 80(627-630 (1998). 
31.     H. Ao et al., "Thermal coagulation-induced changes of the optical properties of normal and 
adenomatous human colon tissues in vitro in the spectral range 400-1,100 nm," Physics in medicine and 
biology 53(8), 2197-2206 (2008). 
32.     V. Gruev et al., "CCD polarization imaging sensor with aluminum nanowire optical filters," Opt 
Express 18(18), 19087-19094 (2010). 
33.     Y. Liu et al., "Complementary fluorescence-polarization microscopy using division-of-focal-
plane polarization imaging sensor," J Biomed Opt 17(11), 116001 (2012). 
34.     S. B. Powell et al., "Calibration methods for division-of-focal-plane polarimeters," Optics 
express 21(18), 21039-21055 (2013). 
35.     Y. Danjo et al., "Actin 'purse string' filaments are anchored by E-cadherin-mediated adherens 
junctions at the leading edge of the epithelial wound, providing coordinated cell movement," Journal of 
cell science 111(22),3323-3332 (1998). 
36.     K. Katoh et al., "Birefringence imaging directly reveals architectural dynamics of filamentous 
actin in living growth cones," Molecular biology of the cell 10(1), 197-210 (1999). 
37.    T. A. Ullman et al., "Intestinal inflammation and cancer," Gastroenterology 140(6), 1807-1816 
(2011). 
38.    R. Kiesslich et al., "Surveillance colonoscopy in ulcerative colitis: magnifying 
chromoendoscopy in the spotlight," Gut 53(2), 165-167 (2004). 
39.    M. Kusano et al., "Sentinel node mapping guided by indocyanine green fluorescence imaging: a 
new method for sentinel node navigation surgery in gastrointestinal cancer," Digestive surgery 25(2), 
103-108 (2008). 
40.    K. Marten et al., "Detection of dysplastic intestinal adenomas using enzyme-sensing molecular 
beacons in mice," Gastroenterology 122(2), 406-414 (2002). 
41.    M. Karin et al., "NF-kappaB: linking inflammation and immunity to cancer development and 
progression," Nature reviews. Immunology 5(10), 749-759 (2005). 
42.     S. I. Grivennikov et al., "Immunity, inflammation, and cancer," Cell 140(6), 883-899 (2010). 
43.     M. B. Wallace et al., "Endoscopic detection of dysplasia in patients with Barrett's esophagus 
using light-scattering spectroscopy," Gastroenterology 119(3), 677-682 (2000). 
44.     K. Sokolov et al., "Reflectance spectroscopy with polarized light: is it sensitive to cellular and 
nuclear morphology," Optics express 5(13), 302-317 (1999) 
 
136 
 
 
 
 
 
 
 
 
Chapter 5 
A NIR-fluorescence imaging platform distinguishes pancreatic cancer and pancreatitis 
non-invasively and guides NIR fluorescence laparoscopy for “smart biopsies” 
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Chapter 5 is a reformatted version of a manuscript in submission: “Tauseef Charanya, Yu Zhu, 
Pinaki Sarder, Joe Culver, David Denardo, Samuel Achilefu et al. A NIR-fluorescence imaging 
platform distinguishes pancreatic cancer and pancreatitis non-invasively and guides NIR 
fluorescence laparoscopy for “smart biopsies”. My contributions to this work included designing 
the experiments, carrying out the imaging studies involving pancreatitis and pancreatic cancer 
models, interpreting and analyzing data, and writing the manuscript. In this chapter, I discuss my 
work in the non-invasive detection of pancreatic cancer versus pancreatitis followed by guided 
intervention NIR laparoscopy approach using NIR targeted probe, LS301. Furthermore, binding 
studies using immunohistochemistry and flow cytometry helped further validate the specificity of 
the molecular probe. 
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Abstract 
Pre-cancerous and cancerous pancreatic lesions typically go undetected and/or undifferentiated 
from pancreatitis by current non-invasive and invasive means, resulting in horrendous prognosis. 
We have developed a NIR fluorescence-based imaging platform consisting of a noninvasive 
fluorescence molecular tomography (FMT) system and a targeted NIR-fluorescent molecular 
probe to distinguish between pancreatitis and pancreatic cancer. This system allows for guided 
interventional fluorescence laparoscopy to ensure complete tumor resection and distinction of 
cancerous lesions from pancreatitis. Using caerulein-treated acute and chronic pancreatitis models 
along with both spontaneous and orthotopic pancreatic cancer models, we demonstrated five-fold 
higher total fluorescence intensity in pancreatic cancer models versus pancreatitis and 8 to 12 fold 
higher tumor-to-background ratios (TBR). Ex-vivo fluorescence binding patterns in pancreatic 
cancer of our molecular probe demonstrated high correlation with the established marker such as 
cytokeratin 19 (CK19).  Flow-cytometry further validated the specific binding and retention of the 
molecular probe in pancreatic tumor cells. Together, the targeted molecular probe and FMT guided 
fluorescence laparoscopy intervention provides a method for early detection of pancreatic cancer 
and non-invasive distinction between cancer and pancreatitis.  
 
Translational Relevance 
Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease with horrendous prognosis. This 
typically arises due to the relatively symptom-free nature of the disease. Moreover, the few 
common symptoms that it does possess are extremely similar to that of pancreatitis. The current 
procedural complexity of the disease has been known to introduce complications of its own. 
Advancements in detection methods from imaging and targeted molecular probe standpoint to 
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allow for non-invasive prognosis prior to any invasive procedure are lacking in specificity and 
sensitivity of detection. Our results have identified a platform of imaging that allows for a non-
invasive distinction of PDAC from pancreatitis prior to a near-infrared-based-laparoscopy 
procedure that allows to collect “smart biopsies”. The targeted molecular probe utilized plays an 
integral role in this platform for its ability to selectively retain in pancreatic tumor cells versus 
normal pancreas. This platform can be easily translated to humans via introducing a nuclear analog 
of this molecular probe to allow for SPECT/PET imaging. 
 
 
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal common cancers, mainly 
because it is usually diagnosed at a very advanced stage. In 2014, there were 46,420 new cases of 
pancreatic cancer with approximately 40,000 deaths in the United States alone1. It has an abysmal 
five year survival rate of <6% and which only increases to 10 to 25% after diagnosis and pancreatic 
head resection2-4. Late stage diagnosis of pancreatic cancer misdiagnosis of the disease with 
pancreatitis and the procedural complexity of obtaining biopsy samples serve as the key reasons 
for poor prognosis.  
Late stage diagnosis in pancreatic cancer is associated with misdiagnosis of the disease as 
pancreatitis and the procedural complexity of obtaining biopsy samples. The distinction between 
pancreatitis, pancreatic intraepithelial neoplasia (PanINs), and pancreatic cancer is extremely 
difficult due to their common clinical symptom presentation such as pain, weight loss, and 
pancreatic endocrine and exocrine dysfunction. The complexity of differential diagnosis is further 
enhanced as pancreatic cancer is frequently associated with secondary inflammatory changes due 
to obstruction of the pancreatic duct5. Furthermore, obtaining tissue samples can be challenging, 
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as imaging studies typically fail to demonstrate an obvious mass. Subsequently, biopsy samples 
may only show a suspicion of neoplasia and not definitively document malignancy, subjecting 
patients to an inherent risk of morbidity via the operating procedure6. The need for accurate 
distinction of pancreatitis from pancreatic cancer and early detection is much desired in clinic. 
Advances in pancreatic imaging provide potential to diagnose early. Cornerstones of 
endoscopic pancreatic imaging are endoscopic retrograde pancreatography (ERP) and endoscopic 
ultrasonography (EUS) with optical coherence tomography (OCT) and confocal laser 
endomicroscopy (CLE) serving as supplements to these methods along with intraductal 
ultrasonography, and enhanced EUS7-12.  ERP has the ability to image the main pancreatic duct 
and is specifically used to identify chronic pancreatitis lesions while EUS, on the other hand, 
allows imaging of both the pancreatic duct as well as the parenchyma13,14. However, in early 
chronic pancreatitis, there are only minimal differences from the normal pancreas, resulting in a 
histological correlation of only 75% using ERP and 80% using EUS7. Furthermore, limitations 
exist in supplement methods to ERP and EUS such as lack of ability to image non-invasively 
and/or to identify pancreatic lesions based on their molecular footprint. As a result, both ERP and 
EUS identify PDAC with limited sensitivity and specificity in patients with chronic pancreatitis 
and are unable to differentiate chronic pancreatitis from PanINs7,15. The need for accurate 
diagnosis non-invasively prior to invasive laparoscopic procedures is much desired due to the 
inherent risk of developing pancreatitis via the ERP procedure itself13-14. 
Targeted molecular imaging is known to identify molecular signatures that distinguish 
cancerous lesions from surrounding tissue, and provide versatility to be combined with a modality 
that provides complementary structural information. Furthermore, it has the ability to image the 
pancreas non-invasively prior to the semi-invasive laparoscopic tumor resection procedure, 
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thereby reducing the risks associated with surgery. For example, Bausch et al isolated a biomarker 
(Plec-1) for pancreatic cancer via phage display and, in combination with a SPECT imaging agent, 
imaged cancerous lesions successfully in mice bearing orthotopic tumors16. However, the ability 
of this probe to distinguish pancreatic cancer from pancreatitis has yet to be explored.  
The overarching goal of this study is twofold, firstly to establish an imaging platform that 
allows for non- invasive distinction between pancreatic cancer and pancreatitis prior to guiding 
NIR laparoscopy for “smart biopsies” and secondly to establish binding preferences of the targeted 
molecular probe in the pancreatic tumor microenvironment. In our study, we utilized fluorescence 
molecular tomography (FMT) prior to guiding a NIR-capable laparoscope for obtaining “smart 
biopsies”. Binding preferences of the molecular probe were analyzed amongst precancerous, 
cancerous, and uninvolved pancreatic tissues utilizing immunohistochemistry and flow-cytometry.  
NIR laparoscopy and ex-vivo imaging of exteriorized pancreas validated differential signatures 
obtained between pancreatitis, and pancreatic cancer via non-invasive FMT. Binding studies 
validated preferential uptake of targeted molecular probe in pancreatic tumor versus pancreaetitis 
and normal pancreas. 
 
Methods and Materials 
Targeted NIR fluorescence molecular probes 
We have previously demonstrated the use of the targeted molecular probe, LS301 in 
epithelial-based cancers and have extended its use towards detection of pancreatic cancer lesions 
in this study17. LS301 and its analog, LS789, were synthesized by a previously described method18. 
LS301 consists of a near-infrared fluorescent dye, cypate (780 ex/ 830 em), and the cyclic peptide 
142 
 
sequence D-Cys-Gly-Arg-Asp-Ser-Pro-Cys-Lys (c(DCGRDSPC)K).  LS789 (680 ex/ 710 em) 
consists of cypate-3 and the peptide sequence cyclo(DCys-Gly-Arg-Asp-Ser-Pro-Cys)-Lys-OH. 
The conjugation of the dye and peptide sequence was characterized by spectroscopy methods, 
analytical HPLC, and electrospray ionization mass spectrometry. 
 
Cell lines and culture 
 We used mouse-derived pancreatic tumor cell lines for development of early and late stage 
orthotopic pancreatic tumor models.  We also utilized mouse derived bone-marrow derived 
macrophages (BMDM) and human pancreatic cell lines for an in vitro binding preference study 
using LS301. 
The KI cell line was derived from pancreatic adenocarcinomas from p48-CRE/LSL-
KrasG12D/INK4aflox19. All cell lines were mycoplasma tested and labeled with a polycistronic 
click beetle red luciferase-mCherry reporter by lentiviral infection. These cells were maintained in 
Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum 
(Hyclone). All cells were cultured in a humidified incubator at 370C with 5% CO2. Bone marrow 
was isolated from the femurs and tibias of wild-type B6 mice. Bone marrow was cultured in 20 
ng/ml of colony stimulating factor-1 (CSF1) for five days. HPAC cells were derived from primary 
PDAC (wild type TP53 and SMAD4 with mutations in KRAS +CDKN2A) (p16) (20). The tumor 
is considered moderately differentiated and of ductal origin. Hs766T cells were derived from a 
lymph node metastasis (wild type KRAS, TP53, CDKN2A) with pancreatic carcinoma20-22. 
 
Animal models 
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All animal studies were performed according to protocols approved by the Washington 
University School of Medicine Animal Studies Committee for humane care and use of laboratory 
animals.  
KPC spontaneous and orthotopic PDAC model 
The well-established spontaneous pancreatic cancer model p48-/Cre+/LSL-KrasG-
12D/p53flox/+ (KPC model) was utilized in this study for its ability to develop a spectrum of 
premalignant pancreatic intraepithelial neoplasias (PANINs) over a two-month period that 
ultimately progressed to carcinoma in five to six months23-24. KPC mice with a palpable tumor at 
the five-six month stage were used for the advanced carcinoma stage and those at two and a half 
month stage were used for the precancerous stage. Synergistic orthotopic PDAC tumors were 
established by injecting 200,000 cells in 50 µL matrigel (BD Biosciences) into each mouse 
pancreas25. Tumors were allowed to grow over one to two weeks to allow for variable tumor sizes 
of less than 0.5 cm and between 1-1.5 cm respectively. 50 µL of matrigel alone was injected into 
the pancreas as control. 
Pancreatitis model 
To induce acute pancreatitis, we performed 7 intraperitoneal injections of 50 µg/kg 
caerulein (Sigma, St. Louis, MO, USA) or vehicle in 0.9% NaCl within a 2 day period26-27. To 
induce chronic pancreatitis, we injected caerulein every other day for two months. 
 
Fluorescence Molecular Tomography (FMT) System 
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FMT system was used as first pass, binary assessment tool for differentiating pancreatic 
cancer from pancreatitis and normal pancreas prior to follow-up investigation using NIR 
laparoscopy. Animal studies were conducted on a recently developed temporally resolved 
fluorescence molecular tomography system28. Briefly, a pulsed supercontinuum laser source (K93-
120-02; 80 MHz, 400-1200 nm, 5-ps pulse width, integrated power over the spectral window is 
~3.5W with 1 mW/nm) was used for illumination. The beam from the laser was expanded ~10 
times using two concave mirrors, and passed through a 769/41 nm Brightline® single-band 
bandpass filter (Semrock, Rochester, NY) for focusing. The beam, after passing through the 
focusing lens, was steered by a pair of galvanometer scanning mirrors to the source side of an 
imaging cassette. Light emitted from the detector plane of the imaging cassette was collected by a 
lens, temporally gated by an ultrafast gated image intensifier, and detected by an electron-
multiplying charge-coupled device camera for read-out. Optional filters in front of the lens allow 
acquisition of either the transmitted excitation or fluorescence emission (832 ± 10 nm). Timing 
between the source and the gated detection was controlled by a programmable delay unit, allowing 
a series of images to capture the light emission as a function of time. A scan resulted in a temporal 
profile of transmitted excitation and stimulated emission at each detector location. From these data, 
we reconstructed a map of fluorescence yield and lifetime simultaneously via a normalized Born 
approach29-30. Specifically, we used an analytical solution to the diffusion equation that 
incorporated absorption and scattering in the light model31. Our studies described in this 
manuscript employed the econstructed fluorescence yield for detection of pancreatic cancer in the 
mice that we imaged. 
 For studies, each mouse was anesthetized with a mixture of ketamine (87mg/kg) and 
xylazine (13 mg/kg) intraperitoneally, prior to scanning. They were then suspended vertically 
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within the optical-matching fluid-filled imaging cassette for duration of the scanning session, as 
previously described28. The role of the optical-matching fluid is to create diffuse optical properties 
that match those of the mouse. Intralipid and India ink are added to deionized (DI) water to reduce 
the scattering coefficient (µs’) and absorption coefficient (µa’) respectively. For the in vivo 
experiments, we use µs’ = 10 cm-1 and µa’ = 0.2 cm-1 to match optical properties of the mouse28.  
Subsequently, a computed tomography (CT) image of the mouse was obtained in the orientation 
it was placed in the cassette, to provide supplementary structural information to FMT data. 
 
Small animal imaging 
Planar imaging systems serve as a reliable tool for biodistribution studies due to their high 
sensitivity of detection along with their ability to reliably resolve depths less than 1 cm (within the 
range of excised tissues). A commercially available fluorescence planar imaging system (LiCor 
Biosciences, Lincoln, Nebraska) was used to perform superficial (<1 cm) NIR fluorescence 
imaging of live mice, and exteriorized organs for validation, post-FMT and NIR laparoscopy 
imaging. The method employed for imaging has been reported previously32. Mice were positioned 
supine on the heated imaging platform. A 785 nm excitation wavelength and 830 nm emission was 
used to conduct in vivo imaging. Scans were obtained immediately, 1 hour, 4 hours, 24 hours, and 
48 hours post administration of imaging agent. The pancreas and/or pancreatic tumor was 
exteriorized prior to imaging and regions of interest (ROIs) were identified. For each selected 
region, the mean fluorescence intensity values for the tumor or pancreas and the surrounding 
region (spleen) were determined and reported for analysis. In cases where tumor had infiltrated to 
the surrounding spleen organ (PDAC two week models), areas of the spleen that weren’t affected 
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were used as a point of reference. Mean fluorescence intensity was determined for each tissue by 
ROI analysis and results were combined for each group for statistical analysis.  
 
Color-NR Endoscope 
 A color-NIR endoscope was utilized in order to guide biopsy post non-invasive imaging 
using (FMT) system. NIR laparoscopy was also performed to validate the findings from FMT and 
ensure complete resection of pancreatic tumor. The NIR color endoscope device developed in our 
lab and used in this study has been previously reported33. Briefly, in color mode, a xenon light 
source with adjustable light intensity was coupled to the illumination channel on a 00 Hopkins (1.9 
mm x 10 cm) straightforward telescope (Karl Storz, Tuttlingen, Germany). A telescope coupler 
with a focus ring focused the CCD camera on the image formation plane at the back of the 
telescope. In the fluorescence mode, a 780 nm mounted LED, 420 mW (Thorlabs, Newton, New 
Jersey) with a 26.5 mm Carco poly-carbonate collimated lens coupled to a 769/41 nm Brightline 
® single-band bandpass filter (Semrock, Rochester, NY) was used. An 808 nm long-pass emission 
filter (Chroma Technology, Bellows Falls, VT) was utilized to ensure capturing the emission 
characteristics of the molecular probe. Images were captured using a NIR-sensitive CCD camera. 
Forty-eight hours after the injection of LS301, mice were anesthetized via intraperitoneal 
injection of a solution of ketamine and xylazine and placed supine on the surgical bed prior to the 
procedure. An incision was made from the epi-gastric/zyphoid process region down to the lower 
abdomen. An exploratory laparotomy was performed around the pancreatic region using color-
NIR laparoscope. Once an identifiable NIR signal was observed, images were captured and the 
corresponding color image was obtained. Similarly, images and the corresponding NIR signals 
were captured of surrounding organs such as spleen, liver, stomach and small intestine.   
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Flow Cytometry Analysis 
In order to better understand the probe binding characteristics, flow cytometry was 
conducted utilizing normal pancreas and orthotopic pancreatic tumor tissue. Mouse tumors or 
normal pancreatic tissues were minced and enzymatically digested into a single cell suspension, 
and incubated with anti-mouse CD16/CD32 antibodies (eBiosciences) to prevent nonspecific 
antibody recognition. Cells were stained for 20 minutes at 40C with 100 μL of fluorophore-
conjugated anti-mouse antibodies [CD3e (145-2C11), CD11b (M1/70), CD19 (MB19-1), CD45 
(30-F11), CD49f (eBioGoH3), CD90 (53-2.1), F4/80 (BM8), Ly6C (HK1.4), Ly6G (1A8), MHCII 
(M5/114.15.2)] (all from eBiosciences) at concentrations recommended by the manufacturer. Data 
was acquired on the LSR-II system (BD Biosciences) and analyzed using the FlowJo software 
version 9.2 (Tree Star).  
 
Immunofluorescence 
Tissues were harvested from mice 48 hours post probe administration, immediately 
embedded in optimal cutting temperature compound, and snap frozen. Six μm thick sections were 
fixed in 4% paraformaldehyde for 15 minutes at room temperature and stained with CK19 
(TROMA-III-c, from Developmental Studies Hybridoma Bank). Olympus BX51 upright 
epifluorescence microscope (Olympus America, Center Valley, PA, USA) was used to image Cy 
5 fluorescence originating from CK19 probe (620 +/- 60 excitation, 700 +/- 75 emission filters 
used), and  NIR fluorescence originating from LS301 molecular probe (775 +/-50 nm excitation, 
810 nm long-pass dichroic, and 845 +/-55 nm emission filters was used). Golds standard 
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hematoxylin and eosin (H&E) staining was conducted to compare fluorescence binding patterns 
with corresponding morphological features of pancreatic tissues. 
 
Internalization Study 
Mouse BMDM and HPAC cells were grown on Lab-Tek slides.  Cells were treated for 6h 
with 1 uM LS301. After the incubation the cells were rinsed one with PBS containing 1 mM 
CaCl2 and imaged with an Olympus FV 1000 confocal microscope, using a 60x water immersion 
objective and a 780 nM laser for excitation. ImageJ software (NIH, Bethesda, Maryland) was used 
to measure and compare the fluorescence intensity values associated with macrophages and tumor 
cells.  
 
Results 
Characterization of molecular probes LS301 and LS789  
LS301 has demonstrated its ability to selectively identify precancerous and cancerous 
lesions in colon cancer, as well as several other adenocarcinomas33-34. In this study we explored 
its use for identifying precancerous and cancerous pancreatic lesions, and differentiating cancer 
from acute and chronic pancreatitis. The use of NIR fluorescence allows us to minimize tissue 
auto-fluorescence and avoid absorption by hemoglobin (<650 nm), and water and lipds (>900 nm). 
This allows for deeper tissue penetration, making non-invasive optical imaging possible. In order 
to better examine the binding preferences of LS301 towards pancreatic cancer and normal pancreas 
tissue, we conducted flow cytometric analyses utilizing several markers to identify specific cell 
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types. Due to lack of ability of the NIR FACS system to image in both the visible (panel of 
markers) and NIR (LS301) fluorescence, we developed an LS301 analog, LS789, which has 
excitation and emission spectra closer to the visible spectrum. The chemical structure and the 
fluorescence spectra (ex/em) of LS301 and LS789 are presented in Figure 1A and 1B, respectively.  
 
Figure 1: Structure and physical characteristics of molecular probes LS301 and LS789. (A) Chemical structure of 
LS301 Cypate-(c(DCGRDSPC)K) and (B) LS789 (analog of LS301)Cypate-3-cyclo(DCys-Gly-Arg-Asp-Ser-Pro-
Cys)-Lys-OH. Note the difference in normalized excitation and emission spectra of LS301 and LS789.   
 
Fluorescence Molecular Tomography (FMT) imaging is able to distinguish PDAC from 
pancreatitis, non-invasively. 
The goal of CT-FMT in this study was to utilize it as a first-pass diagnostic screening tool, 
prior to conducting any invasive laparoscopic procedures. Utilizing the molecular specificity of 
LS301 and overlaying the readout with CT imaging, we can gain insight into both structural and 
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molecular aspects of pancreatic tissue. To test this possibility, we utilized spontaneous KPC 
pancreatic cancer model to recapitulate precancerous (2.5 month stage) and cancerous (5-6 months 
stage; n=3) lesions. Alongside, orthotopic pancreatic cancer models (1 week stage; <0.5 cm tumor 
size, 2 week stage <1 cm tumor size; n=3), pancreatitis models (acute, chronic; n=3), and a control, 
sham surgery model (n=4) were developed to test efficacy of the molecular probe utilizing the 
detection platform. Figure 2 demonstrates the data collected by utilizing this CT-FMT method, 
where we specifically examined the region illustrated in Figure 2A. Unlike the KPC spontaneous 
model, in which the tumor generates within the pancreas, the orthotopic PDAC models presented 
with large tumors engulfed in the pancreatic head closer to the skin, while the tail maintained its 
anatomical position. For this reason, we obtained the signal at six mm depth in all the models to 
capture the pancreas and/or tumor in all models.   
In order to non-invasively distinguish pancreatitis and pancreatic cancer, we utilized total 
fluorescence intensity as a tool for CT-FMT. Total fluorescence intensity was measured by 
summing all the voxels in the region of interest (common amongst all mice imaged). Total 
fluorescence intensity was five fold higher in PDAC and seven fold higher in KPC models than in 
control and acute pancreatitis models. A threshold value of 4E-5 was established for mean 
fluorescence intensity to distinguish pancreatitis and control models from PDAC tumor and KPC 
spontaneous tumors models, as shown in Figure 2B. This metric allowed for a very clear distinction 
between pancreatitis and control models, as compared to tumor models orthotopic and spontaneous 
PDAC.  
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Figure 2: Non-invasive NIR CT-FMT imaging and analysis in control, acute pancreatitis, orthotopic PDAC, and KPC 
PDAC models. (A) Pancreas is outlined by the dotted green line, whereas the region where the implanted tumor 
extends is shown by the dotted red line. Dotted blue line marks the region that was imaged using the FMT system. 
Representative images of various murine models were super-imposed on their respective CT images. (B) Measured 
total fluorescence intensity values compared amongst control, acute pancreatitis, orthotopic and spontaneous PDAC 
models. Dotted green line represents a potential threshold established for the system that distinguishes pancreatitis 
and control from tumor models.  Values represent mean ± SE, n = 3. p < 0.05 
 
A NIR-capable endoscope is able to locate cancerous lesions for “smart biopsies" 
NIR-based laparoscopy was used to validate the FMT findings, isolate precancerous and 
cancerous tissues, and ensure complete tumor resection. The signal established from FMT was 
used as a supplementary tool prior to each mouse surgery, as in certain cases the pancreatic 
tumor was hidden deeper within the core of the mouse’s body as shown in Figure 3A. Having 
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exposed the organs, mice that possessed orthotopically implanted or spontaneously generated 
tumors exhibited eight-ten-fold higher tumor-to-background ratios, whereas early KPC models 
exhibited six-fold higher TBR compared to normal pancreas in the sham surgery model as shown 
in Figure 3B. LS301 demonstrated a 100% specificity and sensitivity towards both precancerous 
and cancerous lesions. The chronic pancreatitis model demonstrated a close to three fold higher 
TBR than the sham surgery model and two fold higher than the acute pancreatitis, likely due to 
acinar to ductal metaplasia associated with prolonged tissue damage via caerulein. 
 
 
 
 
 
 
153 
 
 
Figure 3: In vivo NIR fluorescence laparoscopy and ex-vivo biodistribution imaging of PDAC, pancreatiits, sham 
surgery models A) Brightfield and NIR images are presented with liver (A), stomach (B), pancreas/tumor (C), colon 
(D) and spleen (E). B) Tumor to background ratio measured and recorded by comparing fluorescence intensity values 
of pancreas/tumor and that arising from surrounding spleen region. C) Ex-vivo biodistribution imaging of skin, muscle, 
pancreas/tumor, blood, heart, lung, spleen, kidney and liver of all animal models tested. Normalized mean fluorescence 
intensity values are shown amongst various models: control, acute pancreatitis, and orthotopic PDAC (1 week), 
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orthotopic PDAC (2 week), and KPC tumor models. D) Tumor to background ratio of pancreas/tumor and spleen 
region in each respective model. Values represent mean ± SE, n = 3. p < 0.05 
 
 
Efficacy study in pancreatic cancer and pancreatitis murine models using LS301 
The goal of this portion of this study involving an established small animal imaging 
paradigm was to establish time point that provides maximum contrast between tumor and 
surrounding tissue, and validate findings from FMT and NIR laparoscopy via ex vivo 
biodistribution studies examining exteriorized organs as shown in Figure 3C. Having performed 
in vivo time course imaging on all animal models at 0, 1, 4, 24, and 48h, we obtained optimal 
tumor-to-background ratio (TBR) at 48h (Supplementary Figure 1). Orthotopic pancreatic tumor 
models demonstrated a TBR of 4.2 ± 0.5 and 6.02 ± 0.8, respectively. The KPC advanced tumor 
model demonstrated a TBR of 5.2 ± 0.4 whereas chronic pancreatitis and acute pancreatitis 
demonstrated TBR’s of 1.6 ± 0.2 and 1.5 ± 0.2, respectively as shown in Figure 3D. It is important 
to note, however, that the small planar imaging system is limited to imaging only to depths of 8-
10 mm, as opposed to the DOT which allows us to perform deeper volumetric imaging. 
 
Comparing non-invasive, NIR FMT and guided, invasive NIR laparoscopy with ex-vivo bio-
distribution imaging and validatory H&E  
The TBR ratios obtained post sacrifice and biopsy, as shown in Figure 3D, consistently 
increased from a normal to diseased pancreas state (sham surgery model → acute, chronic 
pancreatitis → pre-cancerous PanIN → overt cancer models (PDAC and advanced KPC)), 
agreeing with the results obtained via FMT and NIR laparoscopy. The mean fluorescence intensity 
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values amongst models tested between FMT, NIR laparoscopy, and established planar imaging 
platform were reported in Figure 4A. Correlation coefficient values of 0.96 were obtained between 
FMT and NIR post-mortem biodistribution and of 0.98 between NIR laparoscopy and post-mortem 
biodistribution. Histological validation of models tested using H&E and their associated 
fluorescence intensities are presented in Figure 4B.  Pancreas and associated tumor slice 
fluorescence shown demonstrates a similar, consistent phenomenon in which control and 
pancreatitis models have minimal NIR fluorescence intensity compared to tumor models. 
Interestingly, the chronic pancreatitis model demonstrated two-fold higher fluorescence intensity 
than the sham surgery model. Having cross-referenced with histology, regions that exhibited 
higher fluorescence intensity patterns appeared to be going through ductal transformation (as a 
result of PanIN progression). 
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Figure 4. Comparing normalized mean fluorescence intensity amongst non-invasive NIR FMT imaging and NIR 
laparoscopy with ex vivo NIR biodistribution and gold-standard H&E. (A) Normalized MFI values compared for 
control, acute pancreatitis, orthotopic PDAC (1 week and 2 weeks) and KPC spontaneous PDAC models. (B) H&E 
and corresponding NIR fluorescence microscopy derived intensity of tissues amongst control, pancreatitis, and tumor 
models. Values represent mean ± SE, n = 3. p < 0.05  
 
Targeted molecular probe LS301 has ability to identify similar regions within pancreatic 
tumors as CK19 
In order to better understand the molecular probe binding preferences, we examined 
pancreatic tissue from pancreatitis, PDAC, and sham surgery models. Binding patters of LS301 to 
the pancreatic tissue were compared to known marker for pancreatic ductal adenocarcinoma, CK19 
as shown in Figure 5. For the sham surgery model, <10% of the cells are CK19+ where only 0% 
of the cells are labeled with LS301. In the acute pancreatitis model, 30% of the cells are CK19+, 
whereas <10% of the cells are labeled with LS301. Orthotopic PDAC 1 week and 2 week models 
along with KPC show more than 60%, 70%, and 70% of the cells to be CK19+, respectively, 
whereas 55%, 75%, and 85% of the cells are labeled with LS301. This level of specificity towards 
precancerous and cancerous lesions prodded us to further investigate and validate binding patterns 
in various cell lines using flow cytometry. 
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Figure 5: Immunohistochemistry and corresponding NIR fluorescence and histological verification in control 
pancreas, KRAS Ink, acute pancreatitis, and spontaneous KPC pancreatic tumor models. A) CK19 (green) binding 
pattern and DAPI (blue) stain of control sham implantation and corresponding NIR (yellow) signal and H&E staining. 
B) CK19 binding pattern and DAPI stain of acute pancreatitis model with corresponding NIR signal and H&E staining. 
C) CK19 binding pattern and mCherry+ (red) tumor cells in KRAS Ink model with DAPI stain and corresponding 
NIR signal. D) CK19 binding pattern and DAPI stain of KPC Spontaneous tumor and corresponding NIR signal and 
H&E staining. Values represent mean ± SE, n = 3. p < 0.05 
 
LS301 and LS789 have binding specificity and selectivity towards pancreatic tumor cells and 
macrophages: a flow cytometry study 
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To determine what cell types within the tumor tissues bound the LS301, we injected LS789, analog 
of LS301, into PDAC tumor-bearing mice and performed flow cytometry analysis on dissociated 
tumor tissue to detect LS789 fluorescence signals in various cell types. Orthotopic PDAC tumor 
models were utilized to examine differences in the uptake of LS789 in a variety of cell types 
present in the tumor tissue or normal pancreas. We found robust uptake in PDAC tumor cells 
compared to normal pancreatic epithelial cells. By contrast internalization of the molecular probe 
was minimal in normal pancreatic cells, normal pancreatic fibroblasts, B cells, T cells and 
neutrophils (Supplementary Figure 2). Modest uptake was observed in tumor macrophages and 
some lower level uptake in tumor associated fibroblasts Figure 6.  The modest uptake in 
macrophages could possibly be explained by phagocytosis of tumor cells that have bound probe. 
80% of TAMs have been shown to have mCherry+ signal, which is derived from pancreatic tumor 
cells35. To distinguish phagocytosis from direct binding, we conducted in vitro studies using 
various pancreatic tumor cell lines and bone marrow derived macrophages (BMDM). PDAC tumor 
cells exhibited significantly higher fluorescent intensity than BMDMs, and this difference was 
greatest at the 6-hr time point. This further accentuates the specificity of the molecular probe 
towards tumor cells and also associates the signal in tumor-associated macrophages, as possibly 
due to phagocytosis or other non-specific uptake mechanisms.   
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Figure 6: FACS data examining LS 789 in distinct tumor infiltrating immune cell types within 
control pancreas (sham implantation) and KRAS Ink pancreatic tumors. Binding was compared 
amongst (A) normal and tumor pancreatic cells, (B) fibroblasts, (C) macrophages, in sham surgery 
and Kras Ink orthotopic implanted tumor-bearing mice. (D) Time-lapse in vitro LS301 binding in 
bone-marrow-derived macrophages (BMDM), normal pancreatic cells, and pancreatic tumor cells. 
(E) Fluorescence intensity distribution in tumor, normal, BMDM at 2h, 4h, 6h. Values represent 
mean ± SE, n = 3. p < 0.05 
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Discussion 
 We have developed an imaging platform that encompasses three elements; a targeted 
molecular probe with enhanced specificity and sensitivity for detection of pancreatic lesions, FMT-
CT for non-invasive differentiation of pancreatitis from pancreatic cancer, and NIR laparoscopy 
to guide “smart” biopsies. Unlike current clinical standards that are reliant on structural 
information and are invasive in nature, FMT-CT coupled with a targeted molecular probe allows 
us to take advantage of molecular-sensitive information associated with tissues and combine it 
with structural information. This combined approach allows for a non-invasive diagnosis method 
for pancreatic cancer versus pancreatitis. Conducting a highly sensitive non-invasive screen prior 
to a semi-invasive laparoscopic procedure, has been shown to reduce the complications associated 
with surgery and lower the risk of developing pancreatitis as a result of surgery.  Furthermore, the 
use of a NIR-capable endoscope allows the surgeon to obtain “smart biopsies” and ensure complete 
resection.  
To best recapitulate progression of pancreatic cancer at various stages, various models were 
employed. Using early and late stage spontaneous pancreatic cancer models, we were able to 
recapitulate pre-cancerous and cancerous lesions, respectively, which best represent human 
pancreatic cancer. Early and late stage orthotopic implantation models provided tumors of varying 
sizes and stages, making imaging systems’ sensitivity in detecting lesions possible to test. Widely 
accepted caerulein-induced acute and chronic pancreatitis models demonstrated an abundance of 
neutrophils, edema, and necrosis, along with regions exhibiting ductal transformation (chronic 
pancreatitis models).   
Our imaging platform is somewhat similar to SPECT-CT, where we have the ability to 
non-invasively identify molecular level information along with structural information. However, 
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due to depth limitations, the FMT imaging platform could be substituted by SPECT-CT by simply 
conjugating a SPECT contrast agent to the molecular probe, while retaining the targeting moiety. 
The versatility of the NIR-FMT was observed in its ability to report on the presence of tumors on 
the surface, as shown by the two-week PDAC orthotopic model, along with tumors up to 10 mm 
deep, such as in KPC model. It even provided the ability to report on tumors with even smaller 
nodules of sizes as low as 0.4 cm (1 week orthotopic PDAC), which was later verified via NIR 
laparoscopy and ex vivo biodistribution studies.  Using metric such as total fluorescence intensity, 
we were able to establish thresholds and clearly distinguish pancreatitis from pancreatic cancer 
non-invasively, as shown in Figure 2. With the molecular probe’s ability to selectively bind to pre-
cancerous and cancerous lesions versus pancreatitis, a SPECT equivalent of the probe has immense 
potential to allow for a similar non-invasive diagnostic platform.    
While the first half of the imaging platform demonstrates great potential for non-invasively 
screening patients for the presence/absence of pancreatic cancer, obtaining “smart” biopsies during 
the laparoscopic procedure still remains a huge concern. Our guided-NIR laparoscopy approach 
allowed us to identify tumors as small as 0.3 cm hidden deep within the cavity of the mouse. 
Furthermore, while the control and acute pancreatitis models demonstrated very minimal 
fluorescent signal, chronic pancreatitis, pre-cancerous and cancerous tumor models (early and late 
stage orthotopic and KPC advanced) demonstrated increasing TBR with disease progression as 
shown in Figure 3B. This trend was further validated ex vivo, as shown in Figure 3C and 3D. NIR 
laparoscopy serves as a strong validatory tool for NIR-FMT and provides a microscopic diagnosis 
of diseased tissue status with the potential to ensure complete tumor removal and minimize 
unnecessary biopsies. 
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The high level of specificity and sensitivity LS301 demonstrated towards pre-cancerous 
and cancerous lesions led us to compare its binding preferences to those of CK19, marker for 
PDAC known to correlate with aggressive phenotypes36. Both LS301 and CK19 binding patterns 
correlated extremely well within pancreatic tumor, and sham surgery models, as shown in Figure 
6. However, the co-localization of binding patterns of LS301 and CK19 were not always similar, 
leading us to further investigate the cell types that exhibited higher uptake of LS301. Having 
conducted a flow cytometry study using control and pancreatic tumor bearing mice as shown in 
Figure 6A, we learned that pancreatic tumors exhibit a greater than 44-fold uptake of LS301 analog 
compared to normal pancreas. However, increased uptake was also observed in macrophages of 
the pancreatic tumor model possibly due to phagocytosis of tumor cells. To distinguish binding 
from phagocytosis, an in vitro study demonstrated four-fold higher uptake of LS301 in tumor cells 
versus BMDM.  
The combination of a tumor-targeting molecular probe with an imaging platform that 
allows for a non-invasive-directed-guided intervention NIR laparoscopy provides a new paradigm 
for the accurate detection of pre-cancerous and cancerous pancreatic lesions versus pancreatitis. 
Moreover, this platform has the potential to stage oncogenesis and improve the management of 
pancreatic cancer in patients. The imaging platform and method described in this study are 
applicable to the assessment of other pathologic conditions, such as upper and lower GI lesions, 
lung carcinoma, and cardiovascular diseases.  
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Chapter 6 
Conclusions 
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 In this dissertation, we have explored a novel way of addressing clinically relevant 
problems such as detection of precancerous and cancerous lesions in colorectal and pancreatic 
cancer. Flat lesions in CAC have been particularly hard to detect given their physical appearance.  
Efforts thus far suffer from poor specificity and sensitivity of detection. We devised a novel 
approach that takes advantage of two modalities which have immense potential in capturing both 
physical as well as molecular abnormalities associated with cancerous lesions. Furthermore, we 
were able to develop a novel topical administration strategy, which ensures even distribution of 
molecular probe for “incubation” and allows for selective uptake. Given the use of dye in 
colonoscopy procedures in cases of dysplasia has become mandatory, this novel method has some 
great potential implications in future practice. Collaborating with clinicians, we were able to 
capture appropriate animal models to best test our FP endoscopy and targeted molecular probe 
approaches. Furthermore, with the complementary fluorescence-polarization microscopy 
approach, we were able to offer a rapid, structural and molecular diagnosis immediately post 
biopsy to potentially circumvent H&E analysis altogether and lower risks associated with repeated 
surgeries. Lastly, we were able to extend our application towards differentiation of pancreatic 
cancer from pancreatitis using the targeted molecular probe and a non-invasive guided imaging 
platform that allows us to take “smart biopsies”. Optical imaging platforms involving 
fluorescence-polarization endoscopy or fluorescence molecular tomography aided laparoscopy for 
invasive or noninvasive diagnostic imaging holds great promise in shifting the paradigm of 
surgical oncology in the future. 
 
 
 
